[go: up one dir, main page]

WO2000031037A1 - Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists - Google Patents

Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists Download PDF

Info

Publication number
WO2000031037A1
WO2000031037A1 PCT/EP1999/009115 EP9909115W WO0031037A1 WO 2000031037 A1 WO2000031037 A1 WO 2000031037A1 EP 9909115 W EP9909115 W EP 9909115W WO 0031037 A1 WO0031037 A1 WO 0031037A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
optionally substituted
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/009115
Other languages
French (fr)
Inventor
Carlo Farina
Giuseppe Giardina
Mario Grugni
Marcel Morvan
Guy Margueritte Marie Gérard NADLER
Luca Francesco Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Laboratoires Pharmaceutiques
GlaxoSmithKline SpA
Original Assignee
SmithKline Beecham Laboratoires Pharmaceutiques
SmithKline Beecham SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9825552.4A external-priority patent/GB9825552D0/en
Priority claimed from GBGB9825553.2A external-priority patent/GB9825553D0/en
Priority to MXPA01005095A priority Critical patent/MXPA01005095A/en
Priority to HU0104959A priority patent/HUP0104959A3/en
Priority to AU17770/00A priority patent/AU768708B2/en
Priority to BR9915475-7A priority patent/BR9915475A/en
Priority to HK02101024.6A priority patent/HK1041257A1/en
Priority to EP99961001A priority patent/EP1131295A1/en
Application filed by SmithKline Beecham Laboratoires Pharmaceutiques, SmithKline Beecham SpA filed Critical SmithKline Beecham Laboratoires Pharmaceutiques
Priority to NZ511777A priority patent/NZ511777A/en
Priority to CA002351865A priority patent/CA2351865A1/en
Priority to IL14313799A priority patent/IL143137A0/en
Priority to KR1020017006343A priority patent/KR20010075726A/en
Priority to JP2000583865A priority patent/JP2002530377A/en
Publication of WO2000031037A1 publication Critical patent/WO2000031037A1/en
Priority to NO20012473A priority patent/NO20012473L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Definitions

  • the present invention relates to novel compounds, in particular to novel quinoline derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds and to the use of such compounds in medicine.
  • the mammalian peptide Neurokinin B belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA).
  • TK Tachykinin
  • SP Substance P
  • NKA Neurokinin A
  • Pharmacological and molecular biological evidence has shown the existence of three subtypes of TK receptor (NK j , N -2 and NK3) and NKB binds preferentially to the NK3 receptor although it also recognises the other two receptors with lower affinity (Maggi et al, 1993, J Auton. Pharmacol., 13, 23-93).
  • NK3 receptor antagonists are known (Drapeau, 1990 Regul. Pept., 31, 125-135), and findings with peptidic NK3 receptor agonists suggest that NKB, by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J.Physiol, 470, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429; Mccarson and Krause, 1994, J Neurosci., 14 (2), 712-720; Arenas et al. 1991, J.Neurosci., 11, 2332-8).
  • the peptide-like nature of the known antagonists makes them likely to be too labile from a metabolic point of view to serve as practical therapeutic agents.
  • Copending International Patent Application number PCT/EP98/03014 discloses certain compounds stated to be non-peptide NK-3 antagonists and also to have NK-2 antagonist activity. These compounds are therefore considered to be of potential use in the prevention and treatment of a wide variety of clinical conditions which are characterized by overstimulation of the tachykinin receptors, in particular NK-3 and NK- 2.
  • NK-3 antagonists which are far more stable from a metabolic point of view than the known peptidic NK-3 receptor antagonists and are of potential therapeutic utility. These compounds also have NK-2 antagonist activity and are therefore considered to be of potential use in the prevention and treatment of a wide variety of clinical conditions which are characterized by overstimulation of the tachykinin receptors, in particular NK-3 and NK-2.
  • respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, airway hyperreactivity, cough; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis and inflammatory pain; neurogenic inflammation or peripheral neuropathy, allergies such as eczema and rhinitis; ophthalmic diseases such as ocular inflammation, conjunctivitis, vernal conjuctivitis and the like; cutaneous diseases, skin disorders and itch, such as cutaneous wheal and flare, contact dermatitis, atopic dermatitis, urticaria and other eczematoid dermatitis; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systhemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative COPD
  • Certain of these compounds also show CNS activity and hence are considered to be of particular use in the treatment of disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease, Down's syndrome, Huntington's disease, Parkinson's disease, movement disorders and convulsive disorders (for example epilepsy); demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy and neuralgia; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; eating disorders (such as food intake disease); fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of the blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud'
  • the compounds of formula (I) are also considered to be useful as diagnostic tools for assessing the degree to which neurokinin-3 and neurokinin-2 receptor activity (normal, overactivity or underactivity) is implicated in a patient's symptoms.
  • Ar is an optionally substituted aryl or a C 5.7 cycloalkdienyl group, or an optionally substituted C5.7 cycloalkyl group, , or an optionally substituted single or fused ring aromatic heterocyclic group;
  • R is hydrogen, linear or branched ⁇ . alkyl, C3-.7 cycloalkyl, C3.7 cycloalkylalkyl;
  • R ⁇ represents hydrogen or up to three optional substituents selected from the list consisting of: C1 _g alkyl, C1.5 alkenyl, aryl, C ⁇ _6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C ⁇ . alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-C ⁇ . alkylamino;
  • R2 represents a moiety -(CH2) n -NY ⁇ Y2 wherein n is an integer in the range of from 1 to 9, Yi and Y2 are independently selected from C ⁇ _6-alkyl; C ⁇ .g alkyl substituted with hydroxy, alkoxy, C ⁇ . alkylamino or bis C ⁇ . alkyl) amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C1 _6-alkenyl; aryl or aryl-C g-alkyl or Y ⁇ and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group;
  • R3 is branched or linear C ⁇ . alkyl, C3.7 cycloalkyl, C4.7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group;
  • R4 represents hydrogen or C ⁇ . alkyl.
  • Rs represents hydrogen or halogen.
  • R 5 represents hydrogen.
  • R5 is chloro or bromo.
  • Ar represents optionally substituted phenyl,unsubstituted phenyl or cyclohexyl.
  • Ar represents cyclohexyl
  • Ar is phenyl or cyclohexyl.
  • R represents C ⁇ -6 alkyl, for example methyl or ethyl or iso-propyl.
  • R is ethyl. In another preferred aspect, R is methyl or isopropyl.
  • R ⁇ represents hydrogen, C ⁇ . alkoxy, for example methoxy, or hydroxy.
  • R ⁇ represents hydrogen.
  • Rl is methoxy or hydroxy.
  • NY1 Y2 represents an optionally substituted N-linked single or fused ring heterocyclic group.
  • Suitable N-linked single or fused heterocyclic groups include groups in which any single or fused ring is saturated or unsaturated and consists of 5- or 6- ring atoms, said ring atoms optionally comprising 1 or 2 additional heteroatoms selected from O or N and wherein one or two ring atoms are optionally substituted with one or two oxo groups or one or two of hydroxy, carboxy, carboxy Cl-6 alkyl, C ⁇ . ⁇ alkoxycarbonyl, aminocarbonyl, Cl-6 alkylcarbonyl optionally substituted with an aromatic heterocyclic group, arylcarbonyl, aryl Cl-6 alkylcarbonyl, carboxy Cl-6 alklycarbonyl, carboxyarylcarbonyl, amino, Cl-6 alkylcarbonylamino, C ⁇ _6 alkyl, C ⁇ . ⁇ hydroxyalkyl, aryl, aryl, Cl-6
  • the additional heteroatom is N.
  • Favoured optional substituents for the N-linked single or fused heterocyclic groups are selected from carboxy Cl-6 alkyl, aminocarbonyl, Cl-6 alkylcarbonyl optionally substituted with an aromatic heterocyclic group, arylcarbonyl, aryl Cl-6 alkylcarbonyl, carboxy Cl-6 alklycarbonyl, carboxyarylcarbonyl, amino, Cl-6 alkylcarbonylamino, C ⁇ . alkyl, C ⁇ .
  • Preferred optional substituents for the N-linked single or fused heterocyclic groups include isopropylcarbonyl, hydroxyethyl, cyclohexyl, phenyl, benzyl, isopropyl, phenethyl, 1-piperidinyl, hydroxyethoxyethyl, (4-hydroxy)-l-piperidinyl, 4- piperidinyl, ( 1 -methyl)-4-piperidinyl, dimethylaminomethylcarbonyl, diethylaminoethylcarbonyl, (4-methy 1)- 1 -piperazinylmethylcarbony 1, 4- morpholinylethylcarbonyl, amino, (4-methyl)-l-piperazinyl, 1-piperazinyl, N-methyl-N'- cyanocarboxamidine, 2-thiazolinyl, pyrrolidinyl-N-cyanomethyleneimine, pyrrolidinyl- N-methylmethy leneimine
  • oxo substituents are preferably alpha to the point of linkage of the N-linked single or fused heterocyclic group.
  • preferred substituents are selected from C . alkyl, hydroxy Cl-6 alkyl for example hydroxyethyl, C3.7 cycloalkyl, C3.7 cycloalkylalkyl, aryl and arylalkyl, for example methyl, ethyl, isopropyl, phenyl,phenethyl, or benzyl, optionally substituted C4- 7 azacycloalkyl for example 4-piperidinyl or (l-methyl)-4-piperidinyl, dialkylaminoalkylcarbonyl for example dimethylaminomethylcarbonyl or diethylaminoethylcarbonyl, hydroxy Cl-6 alkoxy Cl-6 alkyl for example hydroxyethoxyethyl, optionally substituted C4-7 diazacycloalkyl Cl-6 alkylcarbonyl or C4-7 oxaazacycloalkyl Cl-6
  • Fused heterocyclic groups include groups having one or more rings which share one or more atoms, such as spiro fused rings, or one or more bonds.
  • a suitable N-linked single ring heterocyclic group comprising a 5- membered saturated heterocyclic ring is a pyrrolidin -1- yl group.
  • a suitable N-linked single ring heterocyclic group comprising a 6- membered saturated heterocyclic ring is an optionally substituted piperidin-1-yl group, for example a 4-(piperidin-l-yl)piperidin-l-yl group or 4-aminopiperidin-l-yl group.
  • a suitable N-linked single ring 6- membered saturated heterocyclic group comprising an additional heteroatom is an optionally substituted piperazin-lyl group, for example an optionally substituted 4-alkylpiperazin-l-yl group.
  • a suitable N-linked fused ring heterocyclic group includes a 5 -or 6- membered saturated or unsaturated heterocyclic ring fused to a benzene ring.
  • a suitable N-linked fused ring heterocyclic group comprising a 6- membered saturated heterocyclic ring fused to a benzene ring is a 2-(l, 2 ,3 ,4- tetrahydro)isoquinolinyl group.
  • Suitable, N-linked fused heterocyclic groups include spiro fused groups, for example l,4-dioxa-8-azaspiro[4.5]dec-8-yl group or 3-oxo-2,8-diazaspiro[4.5]dec-8-yl or 2,4-dioxo-l,3,8-triazaspiro[4.5]dec-8-yl or 2,7-diazaspiro[4.4]non-2-yl or 2,3-dioxa-l,8- diazaspiro[4.5]dec-8-yl.
  • -NYi Y2 is a piperazin-1-yl group, especially a 4- hydroxyalkylpiperazin-1-yl, or 4-(dialkylaminoalkylcarbonyl)piperazin-l-yl, or 4- (azacycloalkyl)piperazin-l-yl, which piperazinyl group may be substituted or unsubstituted
  • a particularly preferred value of -NY1 Y2 is a group of formula (a), (b) (c) or (d):
  • Tj represents isopropylcarbonyl, hydroxyethyl, cyclohexyl, phenyl, benzyl, isopropyl, phenethyl, 1 -piperidinyl, hydroxyethoxyethyl, (4-hydroxy)-l-piperidinyl, 4- piperidinyl, ( 1 -methyl)-4-piperidinyl, dimethylaminomethylcarbonyl, diethylaminoethylcarbonyl, (4-methy 1)- 1 -piperazinylmethylcarbony 1, 4- morpholinylethylcarbonyl, amino, (4-methyl)-l-piperazinyl, l-piperazinyl, N-methyl-N'- cyanocarboxamidine, 2-thiazolinyl, pyrrolidinyl-N-cyanomethyleneimine, pyrrolidinyl- N-methylmethyleneimine, 1 -pyrrolidiny
  • Ti represents one of the following groups:
  • Re represents H or a lower alkyl, preferably H or methyl
  • m is an integer from 1 to 5
  • R 7 and R 8 represent a lower alkyl, preferably methyl or ethyl or together form an heterocycle, for example a piperidine, mo ⁇ holine or optionally substituted piperazine.
  • Qi represents 2-phthalic acid, a saturated or unsaturated Cl-6 carboxylic acid or an heterocycle for example 2-imidazolyl or thiazolyl.
  • Ti represents also an heterocycle for example imidazolyl, thiazolyl, pyridyl, pyrimidyl, tetrazolyl or Ti represents an optionally substituted carboxamidine or a corresponding quaternary carboxamidine derivative.
  • suitable Ti represents also one of the chemical entities below: wherein R 9 and R ⁇ 0 represent hydrogen, alkyl or together form a 5 to 7 membered ring with the N atom to which they are attached, preferably a pyrrolidin or piperidin ring and R[ i represents C ⁇ -6 linear or branched alkyl or optionally substituted aryl wherein Q 2 is hydrogen, alkyl, aralkyl, aryl, cyano.
  • suitable TI represents also a sulphonamide of formula:
  • R ⁇ 2 and Rj 3 are independently selected from hydrogen; C ⁇ -6 alkyl; optionally substituted aryl or R ⁇ 2 and R [3 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group.
  • -NYi Y2 is a moiety of formula (a). In one particular aspect -NYj Y2 is a moiety of formula (b). In one particular aspect -NYj Y2 is a moiety of formula (c). In one particular aspect -NY1 Y2 is a moiety of formula (d).
  • R3 is optionally substituted aryl, preferably an unsubstituted aryl group such as a phenyl group.
  • R4 is hydrogen
  • n is an integer from 1 to 6, favourably 1 to 4 and most preferably 1 , 2 or 3.
  • n' 1
  • n' represents 2.
  • n' represents 3.
  • Preferred compounds of formula (I) are those wherein: Ar is phenyl or cyclohexyl, R is methyl, ethyl, or isopropyl, R ⁇ is hydrogen or methoxy or hydroxy, R2 is a moiety (CH2)n wherein n is 1, 2, 3 or 4, R3 is phenyl and R4 is hydrogen and NYj Y2 1S :
  • the compounds of formula (I) may have at least one asymmetric centre - for example the carbon atom labelled with an asterisk (*) in the compound of formula (I) - and therefore may exist in more than one stereoisomeric form.
  • the invention extends to all such stereoisomeric forms and to mixtures thereof, including racemates.
  • the invention includes compounds wherein the asterisked carbon atom in formula (I) has the stereochemistry shown in formula (la):
  • the compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • a substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.
  • One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition.
  • the additional ionic and solvent moieties must also be non-toxic.
  • Suitable salts are pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic and methanesulphonic.
  • Suitable pharmaceutically acceptable salts include salts of acidic moieties of the compounds of formula (I) when they are present, for example salts of carboxy groups or phenolic hydroxy groups.
  • Suitable salts of acidic moieties include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl- ⁇ -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
  • metal salts such as for example aluminium, alkali metal salts such as lithium, sodium
  • Suitable solvates are pharmaceutically acceptable solvates.
  • Suitable pharmaceutically acceptable solvates include hydrates.
  • 'alkyl' when used alone or when forming part of other groups (such as the 'alkoxy' group) includes straight- or branched-chain alkyl groups containing 1 to 12 carbon atoms, suitably 1 to 6 carbon atoms, examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl group.
  • 'carbocylic' refers to cycloalkyl and aryl rings.
  • 'cycloalkyl' includes groups having 3 to 12, suitably 4 to 6 ring carbon atoms.
  • 'aryl' includes phenyl and naphthyl, preferably phenyl which unless specified to the contrary optionally comprise up to five, preferably up to three substituents selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxyalkyl, hydroxy, amino, nitro, cyano, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
  • 'aromatic heterocyclic group' includes groups comprising aromatic heterocyclic rings containing from 5 to 12 ring atoms, suitably 5 or 6, and comprising up to four hetero-atoms in the or each ring selected from S, O or N.
  • suitable substituents for any heterocyclic group includes up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted.
  • halogen refers to fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine.
  • acyl includes residues of acids, in particular a residue of a carboxylic acid such as an alkyl- or aryl- carbonyl group.
  • the invention also provides a process for the preparation of a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (II) or an active derivative thereof:
  • R'j, R'2, R'3 and R'5 are R ⁇ , R2, R3 and R5 respectively as defined in relation to formula (I) or a group convertible to R ⁇ , R2, R3 and R5 respectively; with a compound of formula (III):
  • R', R4' and Ar' are R, R4 and Ar as defined for formula (I) or a group or atom convertible to R, R4 and Ar respectively; to form a compound of formula (lb):
  • Suitable groups convertible into other groups include protected forms of said groups.
  • Ar', R', R' j , R' , R'3, R'4 or R' 5 each represents Ar, R, Ri , R 2 , R3, R4 or R5 respectively or a protected form thereof.
  • a suitable active derivative of a compound of formula (II) is a transient activated form of the compound of formula (II) or a derivative wherein the carboxy group of the compound of formula (II) has been replaced by a different group or atom, for example by an acyl halide, preferably a chloride, or an acylazide or a carboxylic acid anhydride.
  • Suitable active derivatives include: a mixed anhydride formed between the carboxyl moiety of the compound of formula (II) and an alkyl chloro formate; an activated ester, such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p- nitrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-hydroxy-phtalimido ester, N-hydroxypiperidine ester, N- hydroxysuccinimide ester, N-hydroxy benzotriazole ester; alternatively, the carboxy group of the compound of formula (II) may be activated using a carbodiimide or N,N'- carbonyldiimidazole.
  • an activated ester such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p
  • reaction between the compound of formula (II) or the active derivative thereof and the compound of formula (III) is carried out under the appropriate conventional conditions for the particular compounds chosen.
  • the reaction is carried out using the same solvent and conditions as used to prepare the active derivative, preferably the active derivative is prepared in situ prior to forming the compound of formula (lb) and thereafter the compound of formula (I) or a salt thereof and/or a solvate thereof is prepared.
  • reaction between an active derivative of the compound of formula (II) and the compound of formula (III) may be carried out:
  • a suitable condensing agent such as for example N,N'-carbonyl diimidazole (CDI) or a carbodiimide such as dicyclohexylcarbodiimide (DCC) or N- dimethylaminopropyl-N'-ethylcarbodiimide, preferably in the presence of N- hydroxybenzotriazole (HOBT) to maximise yields and avoid racemization processes (see Synthesis, 453, 1972), or O-benzotriazol-l-yl-N,N,N',N'- tetramethyluroniumhexafluorophosphate (HBTU), in an aprotic solvent, such as a mixture of acetonitrile (MeCN) and tetrahydrofuran (THF), for example a mixture in a volume ratio of from 1:9 to 7:3 (MeCN:THF), at
  • a compound of formula (lb) may be converted to a compound of formula (I), or one compound of formula (I) may be converted to another compound of formula (I) by interconversion of suitable substituents.
  • certain compounds of formula (I) and (lb) are useful intermediates in forming other compounds of the present invention.
  • the invention provides a process for preparing a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises converting a compound of the above defined formula (lb) wherein at least one of Ar', R', R , R' 2 , R' , R' 4 or R' 5 is not Ar, R, R ⁇ , R2 , R3, R4 or R 5 respectively, thereby to provide a compound of formula (I); and thereafter, as required, carrying out one or more of the following optional steps: (i) converting a compound of formula (I) into another compound of formula (I); and (ii) preparing a salt of the compound of formula (I) and/or a solvate thereof.
  • the variables Ar', R', R'j, R'2, R'3, R'4 and R'5 are Ar, R, Rj, R2, R3, R4 or R5 respectively or they are protected forms thereof.
  • a compound of formula (II) or the corresponding alkyl (such as methyl or ethyl) ester wherein n is an integer 1 is prepared by reacting a compound of formula (IV) or the corresponding alkyl (such as methyl or ethyl) ester:
  • R' ⁇ , R'3 and R'5 are as defined above and ⁇ represents a halogen atom such as a bromine atom, with a compound of formula (V):
  • Y' ⁇ and Y * 2 are Y and Y .
  • reaction between the compounds of formulae (IV) or the corresponding alkyl (such as methyl or ethyl) ester and (V) is carried out under conventional animation conditions, for example when Li is a bromine atom then the reaction is conveniently carried out in an aprotic solvent, such as tetrahydrofuran or dimethylformamide at any temperature providing a suitable rate of formation of the required product, usually at ambient temperature; preferably the reaction is carried out in the presence of triethylamine (TEA) or K 2 CO 3 .
  • TAA triethylamine
  • a compound of formula (IV) or the corresponding alkyl (such as methyl or ethyl) ester is prepared by appropriate halogenation of a compound of formula (VI) or the corresponding alkyl (such as methyl or ethyl) ester: wherein R' ⁇ , R'3 and R'5 are as defined above in relation to formula (II).
  • Suitable halogenation reagents are conventional reagents depending upon the nature of the halogen atom required, for example when L ⁇ is bromine a preferred halogenation reagent is N-bromosuccinimide (NBS).
  • NBS N-bromosuccinimide
  • halogenation of the compound of formula (VI) or the corresponding alkyl (such as methyl or ethyl) ester is carried out under conventional conditions, for example bromination is carried out by treatment with NBS in an inert solvent, such as 1,2- dichloroethane or CH 3 CN, at any temperature providing a suitable rate of formation of the required product, suitably at an elevated temperature such as a temperature in the range of 60°C to 100°C, for example 80°C; preferably the reaction is carried out in the presence of a catalytic amount on benzoyl peroxide.
  • an inert solvent such as 1,2- dichloroethane or CH 3 CN
  • R'3 is as defined in relation to formula (II)
  • T5 is a group - ⁇ Y1Y2 as defined in relation to formula (I) or a protected form thereof or a group convertible thereto
  • p is an integer in the range of 2 to 9; and thereafter as required removing any protecting group and/or converting any group T5 to NY j Y2.
  • the reaction between the compounds of formula (VII) and (VIII) is conveniently carried out using Pfitzinger reaction conditions (see for example J. Prakt. Chem. 33, 100 (1886), J. Prakt. Chem. 38, 582 (1888), J. Chem. Soc. 106 (1948) and Chem. Rev.
  • Groups convertible to -NYj Y2 include groups dictated by conventional chemical practice to be required and to be appropriate, depending upon the specific nature of the - NY1 Y2 consideration.
  • Suitable deprotection methods for deprotecting protected forms of NYi Y2 and conversion methods for converting T5 to NY1Y2 will be those used conventionally in the art depending upon the particular groups under consideration with reference to standard texts such as Greene, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994 and Chemistry of the Amino Group, Patais (Ed.), Interscience, New York 1968; or Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.
  • a compound of formula (VIII) is prepared from a compound of formula (IX):
  • T5 is a group -NY[ Y2
  • a compound capable of forming a group T5 is a compound of the above defined formula (V).
  • halogenation of the compound of formula (IX) is suitably carried out using a conventional halogenation reagent.
  • Mesylation is conveniently carried out using mesyl chloride in an inert solvent such as methylene dichloride, at a temperature below room temperature, such as 0°C, preferably in the presence of triethylamine.
  • reaction conditions between the compound of formula (IX) and the compound capable of forming a group T5 will be those conventional conditions dictated by the specific nature of the reactants, for example when the T5 required is a group NYj Y2 and the required compound capable of forming a group T5 is a compound of the above defined formula (V), then the reaction between the halogenation or mesylation product of the compound of formula (IX) and the compound of formula (V) is carried out under analogous conditions to those described for the reaction between the compounds of formulae (IV) and (V).
  • T5 Other compounds capable of forming a group T5 will depend upon the particular nature of T5, but will be those appropriate compounds dictated by conventional chemical practice with reference to standard texts such asChemistry of the Amino Group, Patais (Ed.), Interscience, New York 1968; and Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.
  • a compound of formula (IX) may be prepared by reacting a compound of formula (IX)
  • reaction between the compounds of formulae (X) and (XI) can be carried out in an aprotic solvent, such as diethyl-ether at any temperature providing a suitable rate of formation of the required product, usually at a low temperature such as in the range of - 10°C to -30°C, for example -20°C.
  • aprotic solvent such as diethyl-ether
  • the compounds of formula (III) are known commercially available compounds or they can be prepared from known compounds by known methods, or methods analogous to those used to prepare known compounds, for example the methods described in Liebigs Ann. der Chemie, (1936), 523, 199.
  • the compounds of formula (V) are known, commercially available compounds or they can be prepared using methods analogous to those used to prepare known compounds; for example the methods described in the Chemistry of the Amino Group, Patais (Ed.), Interscience, New York 1968; Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992 ; J. Heterocyclic Chem. (1990), 27, 1559; Synthesis (1975), 135, Bioorg. Med. Chem. Lett. (1997), 7, 555, or Protective Groups in Organic Synthesis (second edition), Wiley Interscience, (1991) or other methods mentioned herein.
  • 4-amino substituted piperidines are generally prepared by reductive amination of 4-oxo-piperidine, or a 4-oxo-piperidine N-substituted with an appropriated protecting group, with an appropriate amine. Typical examples can be found in J. Org. Chem. (1990), 55 (8), 2552-4 or ibid. (1995), 60 (15), 4928-9.
  • the compounds of formula (VII) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed in J. Org. Chem. 21, 171 (1955); J. Org. Chem. 21, 169 (1955).
  • the compounds of formula (X) and (XI) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed by Krow G. R. in Organic Reactions, Vol 43, page 251, John Wiley & Sons Inc.1994 (for the compounds of formula (X)) and Organometallics in Synthesis, Schlosser M.(Ed), John Wiley & Sons Inc.1994 (for the compounds of formula (XI)).
  • L 2 and L' 2 represent leaving groups such as -SAlkyl or -OAlkyl, preferably -SCH 3 and -OButyl and Ri 1 is as defined above.
  • R[ 2 represents lower alkyl, optionally substituted aryl or aralkyl, followed by the substitution of the group -SCH3, which takes place of the leaving group L 2 , with a compound of formula
  • (XVI) are prepared by reacting a compound of formula (XII) with the benzotriazole derivative of formula (XVII).
  • (CH 2 )n-NY!Y 2 and -NY ⁇ Y 2 is a piperazinyl group of formula (a) wherein TI represents carboxy, alkoxycarbonyl, optionally substituted alkyl, optionally substituted aryl, aralkyl, cycloalkyl, can suitably be prepared by reacting a compound of formula XII with a compound of formula
  • Ti represents one of the radicals defined as above and L3 a leaving group for example halogen or sulfonate, preferably chlorine, bromine or mesylate.
  • Compounds of formula (XII) are prepared by removing the protective group of a compound of formula (XIX) wherein Ar', R', R' ⁇ , R'2, R'3, R'4 and R'5 are as defined above and P is an amine protective group, for example fmoc or benzyl, preferably fmoc.
  • the protective group is removed by standard methods described in the literature, for example the fmoc residue is splitted by action of piperidine at room temperature in a solvent like acetonitrile.
  • the compounds of formula (I) may exist in more than one stereoisomeric form - and the process of the invention may produce racemates as well as enantiomerically pure forms.
  • a pure enantiomer of a compound of formula (I) is obtained by reacting a compound of the above defined formula (II) with an appropriate enantiomerically pure primary amine of formula (Ilia) or (IIIc):
  • R4 represents hydrogen
  • An alternative method for separating optical isomers is to use conventional, fractional separation methods in particular fractional crystallization methods.
  • a pure enantiomer of a compound of formula (I) is obtained by fractional crystallisation of a diastereomeric salt formed by reaction of the racemic compound of formula (I) with an optically active strong acid resolving agent, such as camphosulphonic acid, in an appropriate alcoholic solvent, such as ethanol or methanol, or in a ketonic solvent, such as acetone.
  • the salt formation process should be conducted at a temperature between 20°C and 80°C, preferably at 50°C.
  • a suitable conversion of one compound of formula (I) into a further compound of formula (I) involves converting one group R2 into another group R2 by for example: (i) converting a ketal into a ketone, by such as mild acidic hydrolysis, using for example dilute hydrochloric acid;
  • any group Ar', R, R'j R'2, R'3, R'4 and R'5 into Ar, R, R ⁇ , R2, R3, R4 or R5 which as stated above are usually protected forms of Ar, R, Rj, R2, R3, R4 or R5 may be carried out using appropriate conventional conditions such as the appropriate deprotection procedure.
  • any reactive group in the substrate molecule may be protected and deprotected according to conventional chemical practice, for example as described by Greene-, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994.
  • Suitable protecting groups in any of the above mentioned reactions are those used conventionally in the art.
  • suitable hydroxyl protecting groups include benzyl or trialkylsilyl groups.
  • benzyloxy group may be prepared by treatment of the appropriate compound with a benzyl halide, such as benzyl bromide, and thereafter, if required, the benzyl group may be conveniently removed using catalytic hydrogenation or a mild ether cleavage reagent such as trimethylsilyl iodide or boron tribromide.
  • a benzyl halide such as benzyl bromide
  • the compounds of formula (I) have useful pharmaceutical properties.
  • the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.
  • the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the treatment or prophylaxis of the Primary and Secondary Conditions.
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • the present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Conditions.
  • the Primary conditions include respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, airway hyperreactivity, cough; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis and inflammatory pain; neurogenic inflammation or peripheral neuropathy, allergies such as eczema and rhinitis; ophthalmic diseases such as ocular inflammation, conjunctivitis, vernal conjuctivitis and the like; cutaneous diseases, skin disorders and itch, such as cutaneous wheal and flare, contact dermatitis, atopic dermatitis, urticaria and other eczematoid dermatitis; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systhemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of vis
  • COPD
  • the Secondary conditions include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease, Down's syndrome, Huntington's disease, Parkinson's disease, movement disorders and convulsive disorders (for example epilepsy); demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy and neuralgia; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; eating disorders (such as food intake disease); fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of the blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease and pain or nociception, for example,
  • Such a medicament, and a composition of this invention may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
  • the suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • the compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.
  • the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • compositions may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinyl-pyrrolidone
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
  • compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colour
  • compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • a pharmaceutically acceptable liquid e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the compounds of this invention may also be administered by inhalation, via the nasal or oral routes.
  • administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
  • Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles.
  • the compound particle size is from about 2 to 10 microns.
  • a further mode of administration of the compounds of the invention comprises transdermal delivery utilising a skin-patch formulation.
  • a preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient.
  • pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.
  • the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration.
  • a unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • the composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg.
  • the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.
  • the present invention also provides a method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, non-toxic pharmaceutically acceptable amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • NK3 ligands The activity of the compounds of the present invention, as NK3 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK3 ligands, [ 125 I]- [Me-Phe 7 ]-NKB or [ 3 H]-Senktide, to guinea-pig and human NK3 receptors (Renzetti et al, 1991, Neuropeptide, 18, 104-114; Buell et al, 1992, FEBS, 299(1), 90-95; Chung et al, 1994, Biochem. Biophys. Res. Commun., 198(3), 967-972).
  • the binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [125 _[] v f e _p e ' ' 7 ]-NKB and [ 3 H]- Senktide specific binding to NK3 receptor in equilibrium conditions (IC50).
  • Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate.
  • the most potent compounds of the present invention show IC50 values in the range 0.1-1000 nM.
  • the NK3 -antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J. Pharmacol., 101, 996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991, Eur. J. Pharmacol., 199, 9-14) and human NK3 receptors-mediated Ca " " mobilization (Mochizuki et al, 1994, J.
  • Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean Kg value of 3-8 separate experiments, where Kg is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide.
  • Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca ""1" mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.
  • NK-2 ligands The activity of the compounds of the present invention, as NK-2 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK-2 ligands, [ 125 I]-NKA or [ 3 H]-NKA, to human NK-2 receptors (Aharony et al, 1992, Neuropeptide, 23, 121-130).
  • the binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [125jj_js KA and [ 3 H]-NKA specific binding to NK2 receptor in equilibrium conditions (IC50).
  • Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate.
  • the most potent compounds of the present invention show IC50 values in the range 0.5-1000 nM, such as 1-1000 nM.
  • the NK-2-antagonist activity of the compounds of the present invention is determined by their ability to inhibit human NK-2 receptor-mediated Ca " ⁇ mobilization (Mochizuki et al, 1994, J. Biol. Chem., 269, 9651-9658).
  • Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca " " " mobilization induced by the agonist NKA. In this assay, the compounds of the present invention behave as antagonists.
  • the therapeutic potential of the compounds of the present invention in treating the conditions can be assessed using rodent disease models.
  • the compounds of formula (I) are also considered to be useful as diagnostic tool.
  • the invention includes a compound of formula (I) for use as diagnostic tools for assessing the degree to which neurokinin-3 and neurokinin-2 receptor activity (normal, overactivity or underactivity) is implicated in a patient's symptoms.
  • Such use comprises the use of a compound of formula (I) as an antagonist of said activity, for example including but not restricted to tachykinin agonist-induced inositol phosphate turnover or electrophysiological activation, of a cell sample obtained from a patient. Comparison of such activity in the presence or absence of a compound of formula (I), will disclose the degree of NK-3 and NK-2 receptor involvement in the mediation of agonist effects in that tissue.
  • DESCRIPTION 15 3-[4-(l-Cyanoimino-l-methylsulfanyl-methyI)-piperazin-l- ylmethyI]-2-phenyI-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide
  • DESCRIPTION 16 3-[4-(l-Methanesulfonylimino-l-methylsulfanyl-methyl)- piperazin-l-ylmethyl]-2-phenyl-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)- a ide
  • DESCRIPTION 17 4-[4-((S)-l-Cyclohexyl-ethylcarbamoyl)-2-phenyl-quinolin-3- ylmethyl]-N-methyl-piperazine-l-carboximidothioic acid methyl ester
  • DESCRIPTION 18 3-(4-Oxo-piperidin-l-ylmethyl)-2-phenyl-quinoline-4-carboxyIic acid ((S)-l-phenyl-propyI)-amide
  • the aqueous phase was basified with 1 N NaOH and extracted with EtOAc.
  • the organic phase was dried over Na 2 SO 4 and evaporated to dryness to yield a crude material which was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/hexane 3:7 as eluent. After evaporation of the solvent, 3.0 g of the title compound as a yellow solid were obtained.
  • Table 1 summarizes all the compounds of the Examples 1-95 and their analytical data
  • Table 2 describes NMR spectroscopic data of Examples 1-95
  • Table 3 illustrates chemical names of compounds of Examples 1-95.
  • EXAMPLE 53 ( ⁇ 4-[4-((S)-l-Cyclohexyl-ethylcarbamoyI)-2-phenyI-quinolin-3- ylmethyl]-piperazin-l-yl ⁇ -dimethylamino-methylene)-dimethyl-ammonium hexafluorophosphate 50 mg (0.11 mmol) of the piperazine of Example 34 were reacted with 62 mg (0.16 mmol) of HBTU and 18 mg (0.17 mmol) of triethylamine in a mixture of 1.2 ml of anhydrous THF and 1 ml of CH 2 C1 2 .
  • EXAMPLE 66 S-ll ⁇ 'lBipiperidinyl-l'-ylmethyl-S-bromo-T-methoxy-Z-phenyl- quinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide
  • the catalyst was filtered off, the solvent was evaporated in vacuo to dryness and the residue was purified by gradient flash column chromatography on 230-400 mesh silica gel, utilising EtOAc containing 0.05 % NH 4 OH (28%) as starting eluent, and a mixture of EtOAc/MeOH 95:5 containing 0.05 % N UOH (28%) as final eluent.
  • the residue was dissolved in acetone and acidified with HCl/Et 2 O; the precipitate so formed was recovered by suction filtration to yield 0.1 g of the title compound as a pale yellow solid.
  • EXAMPLE 72 3-[4-(3,4-Dioxo-2-pyrroIidin-l-yl-cyclobut-l-enyI)-piperazin-l- ylmethyl]-2-phenyl-quinoline-4-carboxy lie acid ((S)-l-cyclohexyl-ethyl)-amide
  • the white solid was purified by two successive flash chromatographies on silicagel, eluting first with CH 2 Cl 2 /MeOH : 90/10, then with CH 2 Cl 2 /MeOH/NH 4 OH : 90/10/1. Concentration of the desired fractions gave a solid which was triturated with diethyl ether to afford 0.225 g of the title compound as a salt ofp-toluenesulfonic acid. Analysis of the NMR spectra suggested the occurrence of 1.6 equivalent of acid for one molecule of parent compound (in Table 2, the NMR refers to the parent compound).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A compound, or a solvate or a salt thereof, of formula (I): wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted C5-7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is hydrogen, linear or branched C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, R1 represents hydrogen or up to three optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-C1-6 alkylamino; R2 represents a moiety -(CH2)n-NY1Y2 wherein n is an integrer in the range of from 1 to 9, Y1 and Y2 are independently selected from C1-6- alkyl; C1-6 alkyl substituted with hydroxy, alkoxy, C1-6 alkylamino or bis (C1-6 alkyl)amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C1-6-alkenyl; aryl or aryl-C1-6-alkyl or Y1 and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group; R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or C1-6 alkyl, R5 represents hydrogen or halogen; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

Description

QUIN0LINE-4-CARB0XAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS
The present invention relates to novel compounds, in particular to novel quinoline derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds and to the use of such compounds in medicine.
The mammalian peptide Neurokinin B (NKB) belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA). Pharmacological and molecular biological evidence has shown the existence of three subtypes of TK receptor (NKj, N -2 and NK3) and NKB binds preferentially to the NK3 receptor although it also recognises the other two receptors with lower affinity (Maggi et al, 1993, J Auton. Pharmacol., 13, 23-93).
Selective peptidic NK3 receptor antagonists are known (Drapeau, 1990 Regul. Pept., 31, 125-135), and findings with peptidic NK3 receptor agonists suggest that NKB, by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J.Physiol, 470, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429; Mccarson and Krause, 1994, J Neurosci., 14 (2), 712-720; Arenas et al. 1991, J.Neurosci., 11, 2332-8). However, the peptide-like nature of the known antagonists makes them likely to be too labile from a metabolic point of view to serve as practical therapeutic agents.
Copending International Patent Application number PCT/EP98/03014 discloses certain compounds stated to be non-peptide NK-3 antagonists and also to have NK-2 antagonist activity. These compounds are therefore considered to be of potential use in the prevention and treatment of a wide variety of clinical conditions which are characterized by overstimulation of the tachykinin receptors, in particular NK-3 and NK- 2.
We have now discovered a further novel class of non-peptide NK-3 antagonists which are far more stable from a metabolic point of view than the known peptidic NK-3 receptor antagonists and are of potential therapeutic utility. These compounds also have NK-2 antagonist activity and are therefore considered to be of potential use in the prevention and treatment of a wide variety of clinical conditions which are characterized by overstimulation of the tachykinin receptors, in particular NK-3 and NK-2.
These conditions include respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, airway hyperreactivity, cough; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis and inflammatory pain; neurogenic inflammation or peripheral neuropathy, allergies such as eczema and rhinitis; ophthalmic diseases such as ocular inflammation, conjunctivitis, vernal conjuctivitis and the like; cutaneous diseases, skin disorders and itch, such as cutaneous wheal and flare, contact dermatitis, atopic dermatitis, urticaria and other eczematoid dermatitis; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systhemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), gastro- exophageous reflex disease (GERD); urinary incontinence and disorders of the bladder function; renal disorders (hereinafter referred to as the 'Primary Conditions').
Certain of these compounds also show CNS activity and hence are considered to be of particular use in the treatment of disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease, Down's syndrome, Huntington's disease, Parkinson's disease, movement disorders and convulsive disorders (for example epilepsy); demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy and neuralgia; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; eating disorders (such as food intake disease); fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of the blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the transmission of pain in migraine, (hereinafter referred to as the 'Secondary Conditions').
The compounds of formula (I) are also considered to be useful as diagnostic tools for assessing the degree to which neurokinin-3 and neurokinin-2 receptor activity (normal, overactivity or underactivity) is implicated in a patient's symptoms.
According to the present invention there is provided a compound, or a solvate or a salt thereof, of formula (I):
Figure imgf000004_0001
wherein, Ar is an optionally substituted aryl or a C 5.7 cycloalkdienyl group, or an optionally substituted C5.7 cycloalkyl group, , or an optionally substituted single or fused ring aromatic heterocyclic group;
R is hydrogen, linear or branched \. alkyl, C3-.7 cycloalkyl, C3.7 cycloalkylalkyl;
R\ represents hydrogen or up to three optional substituents selected from the list consisting of: C1 _g alkyl, C1.5 alkenyl, aryl, Cι _6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C\. alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-Cι. alkylamino;
R2 represents a moiety -(CH2)n-NYι Y2 wherein n is an integer in the range of from 1 to 9, Yi and Y2 are independently selected from Cι_6-alkyl; C^.g alkyl substituted with hydroxy, alkoxy, C\. alkylamino or bis C\. alkyl) amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C1 _6-alkenyl; aryl or aryl-C g-alkyl or Y\ and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group;
R3 is branched or linear C\. alkyl, C3.7 cycloalkyl, C4.7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and
R4 represents hydrogen or C\. alkyl.
Rs represents hydrogen or halogen.
Preferably R5 represents hydrogen. In another preferred aspect R5 is chloro or bromo.
Suitably, Ar represents optionally substituted phenyl,unsubstituted phenyl or cyclohexyl.
Suitably, Ar represents cyclohexyl.
Preferably Ar is phenyl or cyclohexyl.
Suitably, R represents Cι-6 alkyl, for example methyl or ethyl or iso-propyl.
In one preferred aspect, R is ethyl. In another preferred aspect, R is methyl or isopropyl.
Suitably R\ represents hydrogen, C\. alkoxy, for example methoxy, or hydroxy.
Preferably, R\ represents hydrogen. In another preferred aspect, Rl is methoxy or hydroxy.
Suitably, NY1 Y2 represents an optionally substituted N-linked single or fused ring heterocyclic group. Suitable N-linked single or fused heterocyclic groups, include groups in which any single or fused ring is saturated or unsaturated and consists of 5- or 6- ring atoms, said ring atoms optionally comprising 1 or 2 additional heteroatoms selected from O or N and wherein one or two ring atoms are optionally substituted with one or two oxo groups or one or two of hydroxy, carboxy, carboxy Cl-6 alkyl, C\.β alkoxycarbonyl, aminocarbonyl, Cl-6 alkylcarbonyl optionally substituted with an aromatic heterocyclic group, arylcarbonyl, aryl Cl-6 alkylcarbonyl, carboxy Cl-6 alklycarbonyl, carboxyarylcarbonyl, amino, Cl-6 alkylcarbonylamino, Cι _6 alkyl, C\.β hydroxyalkyl, aryl, aryl, Cl-6 alkyl, C3.7 cycloalkyl, optionally substituted C4-7 cycloalkenyl, optionally substituted C4-7 azacycloalkyl, optionally substituted C4-7 diazacycloalkyl, optionally substituted C4-7 oxaazacycloalkyl, optionally substituted C4-7 thiazacycloalkyl, optionally substituted C4-7 thiazacycloalkenyl, C3.7 cycloalkylalkyl, hydroxy Cl-6 alkoxy Cl-6 alkyl, Cl-6 alkoxy Cl-6 alkyl, di Cl-6 alkylaminocarbonyl, di Cl-6 alkylamino Cl-6 alkylcarbonyl, optionally substituted C4-7 azacycloalkyl Cl-6 alkylcarbonyl, optionally substituted C4-7 diazacycloaklyl Cl-6 alkylcarbonyl, optionally substituted C4-7oxaazacycloalkyl Cl-6 alkylcarbonyl, optionally susbtituted carboxamidine, Cl-6 alkylaminothiocarbonyl, optionally substituted nitro vinyl, aminosulphonyl, di Cl-6 alklyaminosulphonyl, or an optionally substituted spiroheterocyclic ring or a single or fused ring aromatic heterocyclic group, or the substituents on adjacent ring atoms form a carbocyclic ring; said aryl or aromatic heterocyclic groups being optionally substituted with one or two C1 _β alkyl, alkoxy, hydroxy, halogen or halogenalkyl groups; wherein, unless otherwise defined optionally substituted means substituted with up to three substituents selected from the list consisting of: amino, alkylamino, alkyl, aryl, heterocyclyl, alkylaryl, aralkyl, oxo, hydroxy and nitrile.
Preferably, the additional heteroatom is N.
Favoured optional substituents for the N-linked single or fused heterocyclic groups are selected from carboxy Cl-6 alkyl, aminocarbonyl, Cl-6 alkylcarbonyl optionally substituted with an aromatic heterocyclic group, arylcarbonyl, aryl Cl-6 alkylcarbonyl, carboxy Cl-6 alklycarbonyl, carboxyarylcarbonyl, amino, Cl-6 alkylcarbonylamino, C\. alkyl, C\. hydroxyalkyl, aryl, aryl Cl-6 alkyl, C3.7 cycloalkyl, optionally substituted C4-7 cycloalkenyl, optionally substituted C4-7 azacycloalkyl, optionally substituted C4-7 diazacycloalkyl, optionally substituted C4-7 oxaazacycloalkyl, optionally substituted C4-7 thiazacycloalkyl, optionally substituted C4-7 thiazacycloalkenyl, C3.7 cycloalkylalkyl, hydroxy Cl-6 alkoxy Cl-6 alkyl, Cl-6 alkoxy Cl-6 alkyl, di Cl-6 alkylaminocarbonyl, di Cl-6 alkylamino Cl-6 alkylcarbonyl, optionally substituted C4-7 azacycloalkyl Cl-6 alkylcarbonyl, optionally substituted C4- 7 diazacycloaklyl Cl-6 alkylcarbonyl, optionally substituted C4-7oxaazacycloalkyl Cl-6 alkylcarbonyl, optionally susbtituted carboxamidine, Cl-6 alkylaminothiocarbonyl, optionally substituted nitrovinyl, aminosulphonyl, di Cl-6 alklyaminosulphonyl, or an optionally substituted spiroheterocyclic ring; wherein, unless otherwise defined optionally substituted means substituted with up to three substituents selected from the list consisting of: amino, alkylamino, alkyl, aryl, heterocyclyl, alkylaryl, aralkyl, oxo, hydroxy, nitrile. Preferred optional substituents for the N-linked single or fused heterocyclic groups include isopropylcarbonyl, hydroxyethyl, cyclohexyl, phenyl, benzyl, isopropyl, phenethyl, 1-piperidinyl, hydroxyethoxyethyl, (4-hydroxy)-l-piperidinyl, 4- piperidinyl, ( 1 -methyl)-4-piperidinyl, dimethylaminomethylcarbonyl, diethylaminoethylcarbonyl, (4-methy 1)- 1 -piperazinylmethylcarbony 1, 4- morpholinylethylcarbonyl, amino, (4-methyl)-l-piperazinyl, 1-piperazinyl, N-methyl-N'- cyanocarboxamidine, 2-thiazolinyl, pyrrolidinyl-N-cyanomethyleneimine, pyrrolidinyl- N-methylmethy leneimine, 1 -pyrrolidinyl-2-nitro vinyl, carboxamidine, carboxyethylcarbonyl, pyrrolidinyl-N-methylsulphonylmethyleneimine, (2-carboxy)- phenylcarbonyl, aminosulphonyl, dimethylaminosulphonyl, carboxymethyl.
When present oxo substituents are preferably alpha to the point of linkage of the N-linked single or fused heterocyclic group.
When a hetero atom of the N-linked single or fused heterocyclic group is substituted, preferred substituents are selected from C . alkyl, hydroxy Cl-6 alkyl for example hydroxyethyl, C3.7 cycloalkyl, C3.7 cycloalkylalkyl, aryl and arylalkyl, for example methyl, ethyl, isopropyl, phenyl,phenethyl, or benzyl, optionally substituted C4- 7 azacycloalkyl for example 4-piperidinyl or (l-methyl)-4-piperidinyl, dialkylaminoalkylcarbonyl for example dimethylaminomethylcarbonyl or diethylaminoethylcarbonyl, hydroxy Cl-6 alkoxy Cl-6 alkyl for example hydroxyethoxyethyl, optionally substituted C4-7 diazacycloalkyl Cl-6 alkylcarbonyl or C4-7 oxaazacycloalkyl Cl-6 alkylcarbonyl for example , (4-methyl)-l- piperazinylmethylcarbonyl, 4-morpholinylethylcarbonyl, optionally substituted carboxamidine for example carboxamidine or N-methyl-N'-cyanocarboxamidine, or pyrrolidinyl-N-cyanomethyleneimine or pyrrolidinyl-N-methylmethyleneimine or pyrrolidinyl-N-methylsulphonylmethyleneimine, optionally substituted nitrovinyl for example l-pyrrolidinyl-2-nitrovinyl, optionally substituted C4-7 thiazacycloalkenyl for example 2-thiazolinyl, carboxy Cl-6 alklycarbonyl for example carboxyethylcarbonyl, carboxyarylcarbonyl for example (2-carboxy)-phenylcarbonyl, aminosulphonyl, di Cl-6 alklyaminosulphonyl for example dimethylaminosulphonyl, carboxy C 1 -6 alkyl for example carboxymethyl.
Fused heterocyclic groups include groups having one or more rings which share one or more atoms, such as spiro fused rings, or one or more bonds.
A suitable N-linked single ring heterocyclic group comprising a 5- membered saturated heterocyclic ring is a pyrrolidin -1- yl group.
A suitable N-linked single ring heterocyclic group comprising a 6- membered saturated heterocyclic ring is an optionally substituted piperidin-1-yl group, for example a 4-(piperidin-l-yl)piperidin-l-yl group or 4-aminopiperidin-l-yl group.
A suitable N-linked single ring 6- membered saturated heterocyclic group comprising an additional heteroatom is an optionally substituted piperazin-lyl group, for example an optionally substituted 4-alkylpiperazin-l-yl group.
A suitable N-linked fused ring heterocyclic group includes a 5 -or 6- membered saturated or unsaturated heterocyclic ring fused to a benzene ring.
A suitable N-linked fused ring heterocyclic group comprising a 6- membered saturated heterocyclic ring fused to a benzene ring is a 2-(l, 2 ,3 ,4- tetrahydro)isoquinolinyl group.
Suitable, N-linked fused heterocyclic groups include spiro fused groups, for example l,4-dioxa-8-azaspiro[4.5]dec-8-yl group or 3-oxo-2,8-diazaspiro[4.5]dec-8-yl or 2,4-dioxo-l,3,8-triazaspiro[4.5]dec-8-yl or 2,7-diazaspiro[4.4]non-2-yl or 2,3-dioxa-l,8- diazaspiro[4.5]dec-8-yl.
One preferred value of -NYi Y2 is a piperazin-1-yl group, especially a 4- hydroxyalkylpiperazin-1-yl, or 4-(dialkylaminoalkylcarbonyl)piperazin-l-yl, or 4- (azacycloalkyl)piperazin-l-yl, which piperazinyl group may be substituted or unsubstituted
A particularly preferred value of -NY1 Y2 is a group of formula (a), (b) (c) or (d):
Figure imgf000008_0001
(a) (b) wherein Tj represents isopropylcarbonyl, hydroxyethyl, cyclohexyl, phenyl, benzyl, isopropyl, phenethyl, 1 -piperidinyl, hydroxyethoxyethyl, (4-hydroxy)-l-piperidinyl, 4- piperidinyl, ( 1 -methyl)-4-piperidinyl, dimethylaminomethylcarbonyl, diethylaminoethylcarbonyl, (4-methy 1)- 1 -piperazinylmethylcarbony 1, 4- morpholinylethylcarbonyl, amino, (4-methyl)-l-piperazinyl, l-piperazinyl, N-methyl-N'- cyanocarboxamidine, 2-thiazolinyl, pyrrolidinyl-N-cyanomethyleneimine, pyrrolidinyl- N-methylmethyleneimine, 1 -pyrrolidinyl-2-nitrovinyl, carboxamidine, carboxyethylcarbonyl, pyrrolidinyl-N-methylsulphonylmethyleneimine, (2-carboxy)- phenylcarbonyl, aminosulphonyl, dimethylaminosulphonyl, carboxymethyl. or
Figure imgf000009_0001
(c) (d) wherein Tj together with T2 and the atoms to which each is attached form an optionally substituted single or fused ring heterocyclic group and either T3 together with T4 form an optionally substituted single or fused ring heterocyclic group;
Suitably Ti represents one of the following groups:
Figure imgf000009_0002
Figure imgf000009_0003
wherein Re represents H or a lower alkyl, preferably H or methyl, m is an integer from 1 to 5 and R7 and R8 represent a lower alkyl, preferably methyl or ethyl or together form an heterocycle, for example a piperidine, moφholine or optionally substituted piperazine.
Qi represents 2-phthalic acid, a saturated or unsaturated Cl-6 carboxylic acid or an heterocycle for example 2-imidazolyl or thiazolyl.
In a group of formula (a), suitably Ti represents also an heterocycle for example imidazolyl, thiazolyl, pyridyl, pyrimidyl, tetrazolyl or Ti represents an optionally substituted carboxamidine or a corresponding quaternary carboxamidine derivative.
In a group of formula (a) suitable Ti represents also one of the chemical entities below:
Figure imgf000010_0001
wherein R9 and Rι0 represent hydrogen, alkyl or together form a 5 to 7 membered ring with the N atom to which they are attached, preferably a pyrrolidin or piperidin ring and R[ i represents Cι-6 linear or branched alkyl or optionally substituted aryl wherein Q2 is hydrogen, alkyl, aralkyl, aryl, cyano.
In a group of formula (a) suitable TI represents also a sulphonamide of formula:
SO2NR12R13 wherein Rι2 and Rj3 are independently selected from hydrogen; Cι-6 alkyl; optionally substituted aryl or Rι2 and R[3 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group.
In one particular aspect -NYi Y2 is a moiety of formula (a). In one particular aspect -NYj Y2 is a moiety of formula (b). In one particular aspect -NYj Y2 is a moiety of formula (c). In one particular aspect -NY1 Y2 is a moiety of formula (d).
Suitably, R3 is optionally substituted aryl, preferably an unsubstituted aryl group such as a phenyl group.
Suitably, R4 is hydrogen.
Suitably, n is an integer from 1 to 6, favourably 1 to 4 and most preferably 1 , 2 or 3.
Favourably, n' represents 1.
Favourably, n' represents 2.
Favourably, n' represents 3.
Preferred compounds of formula (I) are those wherein: Ar is phenyl or cyclohexyl, R is methyl, ethyl, or isopropyl, R\ is hydrogen or methoxy or hydroxy, R2 is a moiety (CH2)n wherein n is 1, 2, 3 or 4, R3 is phenyl and R4 is hydrogen and NYj Y2 1S:
(i) an optionally substituted piperazinyl group, especially a moiety of the above defined formula (a);
(ii) a moiety of the above defined formula (b); or (iii) a moiety of the above defined formula (c); or
(iv) a moiety of the above defined formula (d). Further preferred compounds of formula (I) are those wherein: Ar is phenyl or cyclohexyl, R is methyl, ethyl or isopropyl, R\ is hydrogen, methoxy or hydroxy R2 is a moiety -(CH2)n-NYιY2 wherein n is I .3 is phenyl and R4 is hydrogen and NY1Y2 is:
(i) an optionally substituted piperazinyl group, especially a moiety of the above defined formula (a); or
(ii) a moiety of the above defined formula (b).
In particular should be mentioned the compounds of examples 20, 29, 32, 33, 34, 46, 47, 48, 53, 55, 62, 67, 78, 79, 80, 81 and 95.
The compounds of formula (I) may have at least one asymmetric centre - for example the carbon atom labelled with an asterisk (*) in the compound of formula (I) - and therefore may exist in more than one stereoisomeric form. The invention extends to all such stereoisomeric forms and to mixtures thereof, including racemates. In particular, the invention includes compounds wherein the asterisked carbon atom in formula (I) has the stereochemistry shown in formula (la):
Figure imgf000011_0001
wherein Ar, R, Ri , R2, R3, R4 and R5 are as defined in relation to formula (I).
The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.
One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic. Suitable salts are pharmaceutically acceptable salts.
Suitable pharmaceutically acceptable salts include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic and methanesulphonic.
Suitable pharmaceutically acceptable salts include salts of acidic moieties of the compounds of formula (I) when they are present, for example salts of carboxy groups or phenolic hydroxy groups.
Suitable salts of acidic moieties include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-β-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
Suitable solvates are pharmaceutically acceptable solvates.
Suitable pharmaceutically acceptable solvates include hydrates.
The term 'alkyl' (unless specified to the contrary) when used alone or when forming part of other groups (such as the 'alkoxy' group) includes straight- or branched-chain alkyl groups containing 1 to 12 carbon atoms, suitably 1 to 6 carbon atoms, examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl group.
The term 'carbocylic' refers to cycloalkyl and aryl rings.
The term 'cycloalkyl' includes groups having 3 to 12, suitably 4 to 6 ring carbon atoms.
The term 'aryl' includes phenyl and naphthyl, preferably phenyl which unless specified to the contrary optionally comprise up to five, preferably up to three substituents selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxyalkyl, hydroxy, amino, nitro, cyano, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
The term 'aromatic heterocyclic group' includes groups comprising aromatic heterocyclic rings containing from 5 to 12 ring atoms, suitably 5 or 6, and comprising up to four hetero-atoms in the or each ring selected from S, O or N. Unless specified to the contrary, suitable substituents for any heterocyclic group includes up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted.
When used herein the term "halogen" refers to fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine.
When used herein the term "acyl" includes residues of acids, in particular a residue of a carboxylic acid such as an alkyl- or aryl- carbonyl group.
The invention also provides a process for the preparation of a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (II) or an active derivative thereof:
Figure imgf000013_0001
wherein R'j, R'2, R'3 and R'5 are R\, R2, R3 and R5 respectively as defined in relation to formula (I) or a group convertible to R\, R2, R3 and R5 respectively; with a compound of formula (III):
Ar'
R'
R (III)
wherein R', R4' and Ar' are R, R4 and Ar as defined for formula (I) or a group or atom convertible to R, R4 and Ar respectively; to form a compound of formula (lb):
Figure imgf000013_0002
wherein Ar', R', R'ι , R'2, R'3, R'4 and R'5 are as defined above, and thereafter carrying out one or more of the following optional steps:
(i) converting any one of Ar', R', R'1 ? R'2, R'3, R'4 and R'5 to Ar, R, R\, R2, R3, R4 or R5 respectively as required, to obtain a compound of formula (I);
(ii) converting a compound of formula (I) into another compound of formula (I); and
(iii) preparing a salt of the compound of formula (I) and/or a solvate thereof.
Suitable groups convertible into other groups include protected forms of said groups.
Suitably Ar', R', R'j, R' , R'3, R'4 or R'5 each represents Ar, R, Ri , R2, R3, R4 or R5 respectively or a protected form thereof.
It is favoured if the compound of formula (II) is present as an active derivative.
A suitable active derivative of a compound of formula (II) is a transient activated form of the compound of formula (II) or a derivative wherein the carboxy group of the compound of formula (II) has been replaced by a different group or atom, for example by an acyl halide, preferably a chloride, or an acylazide or a carboxylic acid anhydride.
Other suitable active derivatives include: a mixed anhydride formed between the carboxyl moiety of the compound of formula (II) and an alkyl chloro formate; an activated ester, such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p- nitrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-hydroxy-phtalimido ester, N-hydroxypiperidine ester, N- hydroxysuccinimide ester, N-hydroxy benzotriazole ester; alternatively, the carboxy group of the compound of formula (II) may be activated using a carbodiimide or N,N'- carbonyldiimidazole.
The reaction between the compound of formula (II) or the active derivative thereof and the compound of formula (III) is carried out under the appropriate conventional conditions for the particular compounds chosen. Generally, when the compound of formula (II) is present as an active derivative the reaction is carried out using the same solvent and conditions as used to prepare the active derivative, preferably the active derivative is prepared in situ prior to forming the compound of formula (lb) and thereafter the compound of formula (I) or a salt thereof and/or a solvate thereof is prepared.
For example, the reaction between an active derivative of the compound of formula (II) and the compound of formula (III) may be carried out:
(a) by first preparing an acid chloride and then coupling said chloride with the compound of formula (III) in the presence of an inorganic or organic base in a suitable aprotic solvent such as dimethylformamide (DMF) at a temperature in a range from -70 to 50°C (preferably in a range from -10 to 20°C); or
(b) by treating the compound of formula (II) with a compound of formula (III) in the presence of a suitable condensing agent, such as for example N,N'-carbonyl diimidazole (CDI) or a carbodiimide such as dicyclohexylcarbodiimide (DCC) or N- dimethylaminopropyl-N'-ethylcarbodiimide, preferably in the presence of N- hydroxybenzotriazole (HOBT) to maximise yields and avoid racemization processes (see Synthesis, 453, 1972), or O-benzotriazol-l-yl-N,N,N',N'- tetramethyluroniumhexafluorophosphate (HBTU), in an aprotic solvent, such as a mixture of acetonitrile (MeCN) and tetrahydrofuran (THF), for example a mixture in a volume ratio of from 1:9 to 7:3 (MeCN:THF), at any temperature providing a suitable rate of formation of the required product, such as a temperature in the range of from -70 to 50°C, preferably in a range of from -10 to 25°C, for example at 0°C.
A preferred reaction is set out in Scheme 1 shown below:
Scheme 1
Figure imgf000015_0001
wherein Ar', R', R'ι, R' , R'3, R'4 and R5 are as defined above.
It will be appreciated that a compound of formula (lb) may be converted to a compound of formula (I), or one compound of formula (I) may be converted to another compound of formula (I) by interconversion of suitable substituents. Thus, certain compounds of formula (I) and (lb) are useful intermediates in forming other compounds of the present invention.
Accordingly, in a further aspect the invention provides a process for preparing a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises converting a compound of the above defined formula (lb) wherein at least one of Ar', R', R , R'2, R' , R'4 or R'5 is not Ar, R, R\ , R2 , R3, R4 or R5 respectively, thereby to provide a compound of formula (I); and thereafter, as required, carrying out one or more of the following optional steps: (i) converting a compound of formula (I) into another compound of formula (I); and (ii) preparing a salt of the compound of formula (I) and/or a solvate thereof.
Suitably, in the compound of formula (lb) the variables Ar', R', R'j, R'2, R'3, R'4 and R'5 are Ar, R, Rj, R2, R3, R4 or R5 respectively or they are protected forms thereof.
The above mentioned conversions, protections and deprotections are carried out using the appropriate conventional reagents and conditions and are further discussed below.
A compound of formula (II) or the corresponding alkyl (such as methyl or ethyl) ester wherein n is an integer 1 , is prepared by reacting a compound of formula (IV) or the corresponding alkyl (such as methyl or ethyl) ester:
Figure imgf000016_0001
wherein R'ι, R'3 and R'5 are as defined above and \ represents a halogen atom such as a bromine atom, with a compound of formula (V):
HNNtY'2 (V) wherein Y'j and Y'2 are respectively Y\ and Y2 as defined in relation to formula (I) or protected forms thereof.
Suitably, Y'\ and Y* 2 are Y and Y .
Suitably, reaction between the compounds of formulae (IV) or the corresponding alkyl (such as methyl or ethyl) ester and (V) is carried out under conventional animation conditions, for example when Li is a bromine atom then the reaction is conveniently carried out in an aprotic solvent, such as tetrahydrofuran or dimethylformamide at any temperature providing a suitable rate of formation of the required product, usually at ambient temperature; preferably the reaction is carried out in the presence of triethylamine (TEA) or K2CO3.
A compound of formula (IV) or the corresponding alkyl (such as methyl or ethyl) ester is prepared by appropriate halogenation of a compound of formula (VI) or the corresponding alkyl (such as methyl or ethyl) ester:
Figure imgf000017_0001
wherein R'\, R'3 and R'5 are as defined above in relation to formula (II).
Suitable halogenation reagents are conventional reagents depending upon the nature of the halogen atom required, for example when L\ is bromine a preferred halogenation reagent is N-bromosuccinimide (NBS).
The halogenation of the compound of formula (VI) or the corresponding alkyl (such as methyl or ethyl) ester is carried out under conventional conditions, for example bromination is carried out by treatment with NBS in an inert solvent, such as 1,2- dichloroethane or CH3CN, at any temperature providing a suitable rate of formation of the required product, suitably at an elevated temperature such as a temperature in the range of 60°C to 100°C, for example 80°C; preferably the reaction is carried out in the presence of a catalytic amount on benzoyl peroxide.
In the case in which the corresponding alkyl (such as methyl or ethyl) ester of compounds (VI), (IV) and (II) are utilised, an hydrolysis to compound (II) is required before conversion to compound (lb) in Scheme 1. Such hydrolysis can be carried out under acidic conditions, such 10-36% hydrochloric acid at a temperature in the range between 30 and 100 °C. A compound of formula (II) wherein R'2 represents -
(CH2)2-9"NYιY2, is conveniently prepared by reacting a compound of formula (VII):
Figure imgf000017_0002
wherein R\ and R'5 are as defined in relation to formula (II), with a compound of formula (VIII):
R, CO — CH, — (CH2)p — T
(VIII)
wherein R'3 is as defined in relation to formula (II), and T5 is a group -ΝY1Y2 as defined in relation to formula (I) or a protected form thereof or a group convertible thereto, and p is an integer in the range of 2 to 9; and thereafter as required removing any protecting group and/or converting any group T5 to NYj Y2. The reaction between the compounds of formula (VII) and (VIII) is conveniently carried out using Pfitzinger reaction conditions (see for example J. Prakt. Chem. 33, 100 (1886), J. Prakt. Chem. 38, 582 (1888), J. Chem. Soc. 106 (1948) and Chem. Rev. 35, 152 (1944)), for example in an alkanolic solvent such as ethanol, at any temperature providing a suitable rate of formation of the required product, but generally at an elevated temperature, such as the reflux temperature of the solvent, and preferably in the presence of a base such as potassium hydroxide or potassium tert-butoxide.
Protected forms of -NYj Y2 will vary according to the particular nature of the group being protected but will be chosen in accordance with normal chemical practice.
Groups convertible to -NYj Y2 include groups dictated by conventional chemical practice to be required and to be appropriate, depending upon the specific nature of the - NY1 Y2 consideration.
Suitable deprotection methods for deprotecting protected forms of NYi Y2 and conversion methods for converting T5 to NY1Y2 will be those used conventionally in the art depending upon the particular groups under consideration with reference to standard texts such as Greene, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994 and Chemistry of the Amino Group, Patais (Ed.), Interscience, New York 1968; or Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.
A compound of formula (VIII) is prepared from a compound of formula (IX):
R3'— CO — CH2— (CH2) ~OH wherein R'3 is as defined in relation to formula (II) and p is as defined in relation to formula (VIII), by first halogenating, preferably brominating, or mesylating the compound of formula (IX) and thereafter reacting the halogenation or mesylation product so formed with a compound capable of forming a group T5 so as to provide the required comound of formula (VII).
When T5 is a group -NY[ Y2, a compound capable of forming a group T5, is a compound of the above defined formula (V).
The halogenation of the compound of formula (IX) is suitably carried out using a conventional halogenation reagent. Mesylation is conveniently carried out using mesyl chloride in an inert solvent such as methylene dichloride, at a temperature below room temperature, such as 0°C, preferably in the presence of triethylamine. The reaction conditions between the compound of formula (IX) and the compound capable of forming a group T5 will be those conventional conditions dictated by the specific nature of the reactants, for example when the T5 required is a group NYj Y2 and the required compound capable of forming a group T5 is a compound of the above defined formula (V), then the reaction between the halogenation or mesylation product of the compound of formula (IX) and the compound of formula (V) is carried out under analogous conditions to those described for the reaction between the compounds of formulae (IV) and (V).
Other compounds capable of forming a group T5 will depend upon the particular nature of T5, but will be those appropriate compounds dictated by conventional chemical practice with reference to standard texts such asChemistry of the Amino Group, Patais (Ed.), Interscience, New York 1968; and Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.
A compound of formula (IX) may be prepared by reacting a compound of formula
Figure imgf000019_0001
wherein p is as defined in relation to formula (VIII), with a lithium salt of formula (XI):
R,3 Ll (XI) wherein R'3 is as defined in relation to formula (II).
The reaction between the compounds of formulae (X) and (XI) can be carried out in an aprotic solvent, such as diethyl-ether at any temperature providing a suitable rate of formation of the required product, usually at a low temperature such as in the range of - 10°C to -30°C, for example -20°C.
The compounds of formula (III) are known commercially available compounds or they can be prepared from known compounds by known methods, or methods analogous to those used to prepare known compounds, for example the methods described in Liebigs Ann. der Chemie, (1936), 523, 199.
Chiral compound of formula (III) wherein Ar is a C or C cycloalkyl group, R is methyl and R4 is H are described in J. Org. Chem. (1996), 61 (12), 4130-4135. A chiral compound of formula (III) wherein Ar is phenyl, R is isopropyl and R* is H is a known compound described in for example Tetrahedron Lett. (1994), 35(22), 3745-6. The compounds of formula (V) are known, commercially available compounds or they can be prepared using methods analogous to those used to prepare known compounds; for example the methods described in the Chemistry of the Amino Group, Patais (Ed.), Interscience, New York 1968; Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992 ; J. Heterocyclic Chem. (1990), 27, 1559; Synthesis (1975), 135, Bioorg. Med. Chem. Lett. (1997), 7, 555, or Protective Groups in Organic Synthesis (second edition), Wiley Interscience, (1991) or other methods mentioned herein.
4-amino substituted piperidines are generally prepared by reductive amination of 4-oxo-piperidine, or a 4-oxo-piperidine N-substituted with an appropriated protecting group, with an appropriate amine. Typical examples can be found in J. Org. Chem. (1990), 55 (8), 2552-4 or ibid. (1995), 60 (15), 4928-9.
Certain diazaspirononane intermediates used herein are known compounds, for example that used to prepare example 68 is described in J. Med. Chem. (1990), 33 (8), 2270-2275.
The condensation of succinic and phthalic anhydrides used to generate examples 83 and 85-87 is described in J. Indian Chem. Soc. (1979), 56 (2), 171-2. 4-Heterocyclic substituted piperidine as used for the preparation of example 77 are described in US 4329348 A 19820511.
The compounds of formula (VII) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed in J. Org. Chem. 21, 171 (1955); J. Org. Chem. 21, 169 (1955).
The compounds of formula (X) and (XI) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed by Krow G. R. in Organic Reactions, Vol 43, page 251, John Wiley & Sons Inc.1994 (for the compounds of formula (X)) and Organometallics in Synthesis, Schlosser M.(Ed), John Wiley & Sons Inc.1994 (for the compounds of formula (XI)).
Compounds of formula (I) wherein R2 represents a moiety -(CH2)n-NYιY2 and - NYN2 is a piperazinyl group of formula (a) can suitably be prepared by reacting a compound of formula XII
Figure imgf000020_0001
wherein Ar', R', R'j, R'2, R'3, R'4 and R'5 are as defined above, with reactive species of formula (XIII), for example:
Figure imgf000021_0001
Xllla Xlllb Xlllc Xllld wherein L2 and L'2 represent leaving groups such as -SAlkyl or -OAlkyl, preferably -SCH3 and -OButyl and Ri 1 is as defined above.
Mono substitution of compounds of formula (XIII) by a compound of formula (XII) generates news structures bearing still one leaving group, L'2, which can then be reacted with compounds of formula:
HNR9Rιo wherein R9 and Rio are as defined above to give the final compounds of formula (I).
Substituted carboxamidinopiperazines are best prepared by reacting compounds of formula (XII) with substituted isothiocyanates following scheme 2
Scheme 2
Figure imgf000021_0002
wherein R[2 represents lower alkyl, optionally substituted aryl or aralkyl, followed by the substitution of the group -SCH3, which takes place of the leaving group L2, with a compound of formula
HNR9Rιo as mentioned above.
Unsubstituted carboxamidinopiperazines of formula (XVI)
Figure imgf000022_0001
(XVI) are prepared by reacting a compound of formula (XII) with the benzotriazole derivative of formula (XVII).
Figure imgf000022_0002
(Dimethylaminolethylene)dimethylammonium piperazines of formula (XVIII)
Figure imgf000022_0003
(XVIII) are prepared by heating a compound of formula (XII) with HBTU in the presence of a base, for example TEA, in an appropriate solvent, usually one, or a mixture, of those used in peptide coupling reactions. Compounds of formula (I) wherein R2 represents a moiety -
(CH2)n-NY!Y2 and -NYιY2 is a piperazinyl group of formula (a) wherein TI represents carboxy, alkoxycarbonyl, optionally substituted alkyl, optionally substituted aryl, aralkyl, cycloalkyl, can suitably be prepared by reacting a compound of formula XII with a compound of formula
T ,L3
Wherein Ti represents one of the radicals defined as above and L3 a leaving group for example halogen or sulfonate, preferably chlorine, bromine or mesylate.
Compounds of formula (XII) are prepared by removing the protective group of a compound of formula (XIX)
Figure imgf000023_0001
wherein Ar', R', R'\, R'2, R'3, R'4 and R'5 are as defined above and P is an amine protective group, for example fmoc or benzyl, preferably fmoc. The protective group is removed by standard methods described in the literature, for example the fmoc residue is splitted by action of piperidine at room temperature in a solvent like acetonitrile.As hereinbefore mentioned, the compounds of formula (I) may exist in more than one stereoisomeric form - and the process of the invention may produce racemates as well as enantiomerically pure forms. Accordingly, a pure enantiomer of a compound of formula (I) is obtained by reacting a compound of the above defined formula (II) with an appropriate enantiomerically pure primary amine of formula (Ilia) or (IIIc):
Figure imgf000023_0002
(Ilia) (IIIc) wherein R', R'4 and Ar' are as defined above, to obtain a compound of formula (Fa) or (I'c):
Figure imgf000023_0003
(I'a) (I'c) wherein Ar', R', ], R'2, R'3, R'4 and R'5 are as defined above. Compounds of formula (I'a) or (I'c) may subsequently be converted to compounds of formula (la) or (Ic) by the methods of conversion mentioned before:
Figure imgf000024_0001
(la) (Ic)
wherein Ar, R, R\ R2 , R3, R4 and R5 are as defined above.
Suitably, in the above mentioned compounds of formulae (la), (Ic), (I'a), (I'c), (Ilia) and (IIIc) R4 represents hydrogen.
An alternative method for separating optical isomers is to use conventional, fractional separation methods in particular fractional crystallization methods. Thus, a pure enantiomer of a compound of formula (I) is obtained by fractional crystallisation of a diastereomeric salt formed by reaction of the racemic compound of formula (I) with an optically active strong acid resolving agent, such as camphosulphonic acid, in an appropriate alcoholic solvent, such as ethanol or methanol, or in a ketonic solvent, such as acetone. The salt formation process should be conducted at a temperature between 20°C and 80°C, preferably at 50°C.
In the case in which other basic functionalities, such as primary, secondary or tertiary amine, are present in the molecule, a wider range of optically active acid resolving agents become available, including tartaric acid, O,O'-di-p-toluoyltartaric acid and mandelic acid.
A suitable conversion of one compound of formula (I) into a further compound of formula (I) involves converting one group R2 into another group R2 by for example: (i) converting a ketal into a ketone, by such as mild acidic hydrolysis, using for example dilute hydrochloric acid;
(ii) reducing a ketone to a hydroxyl group by use of a borohydride reducing agent; (iii) converting a carboxylic ester group into a carboxyl group using basic hydrolysis; and/or
(iv) reducing a carboxylic ester group to a hydroxymethyl group, by use of a borohydride reducing agent.
As indicated above, where necessary, the conversion of any group Ar', R, R'j R'2, R'3, R'4 and R'5 into Ar, R, R\, R2, R3, R4 or R5 which as stated above are usually protected forms of Ar, R, Rj, R2, R3, R4 or R5 may be carried out using appropriate conventional conditions such as the appropriate deprotection procedure. It will be appreciated that in any of the above mentioned reactions any reactive group in the substrate molecule may be protected and deprotected according to conventional chemical practice, for example as described by Greene-, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994.
Suitable protecting groups in any of the above mentioned reactions are those used conventionally in the art. Thus, for example suitable hydroxyl protecting groups include benzyl or trialkylsilyl groups.
The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected. Thus for example a benzyloxy group may be prepared by treatment of the appropriate compound with a benzyl halide, such as benzyl bromide, and thereafter, if required, the benzyl group may be conveniently removed using catalytic hydrogenation or a mild ether cleavage reagent such as trimethylsilyl iodide or boron tribromide.
As indicated above, the compounds of formula (I) have useful pharmaceutical properties.
Accordingly the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.
In particular, the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the treatment or prophylaxis of the Primary and Secondary Conditions.
The present invention further provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Conditions.
As mentioned abvove the Primary conditions include respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, airway hyperreactivity, cough; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis and inflammatory pain; neurogenic inflammation or peripheral neuropathy, allergies such as eczema and rhinitis; ophthalmic diseases such as ocular inflammation, conjunctivitis, vernal conjuctivitis and the like; cutaneous diseases, skin disorders and itch, such as cutaneous wheal and flare, contact dermatitis, atopic dermatitis, urticaria and other eczematoid dermatitis; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systhemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), gastro- exophageous reflex disease (GERD); urinary incontinence and disorders of the bladder function; renal disorders..
As mentioned abvove, the Secondary conditions include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease, Down's syndrome, Huntington's disease, Parkinson's disease, movement disorders and convulsive disorders (for example epilepsy); demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy and neuralgia; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; eating disorders (such as food intake disease); fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of the blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the transmission of pain in migraine.
Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
These conventional excipients may be employed for example as in the preparation of compositions of known agents for treating the conditions.
Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration. The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.
Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
The compounds of this invention may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
The compounds of this invention may also be administered by inhalation, via the nasal or oral routes. Such administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles. Preferably, the compound particle size is from about 2 to 10 microns.
A further mode of administration of the compounds of the invention comprises transdermal delivery utilising a skin-patch formulation. A preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient. For a constant rate of percutaneous absoφtion, pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.
As mentioned above, the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg. The composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.
No unacceptable toxicologicai effects are expected with compounds of the invention when administered in accordance with the invention.
The present invention also provides a method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, non-toxic pharmaceutically acceptable amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
The activity of the compounds of the present invention, as NK3 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK3 ligands, [125I]- [Me-Phe7]-NKB or [3H]-Senktide, to guinea-pig and human NK3 receptors (Renzetti et al, 1991, Neuropeptide, 18, 104-114; Buell et al, 1992, FEBS, 299(1), 90-95; Chung et al, 1994, Biochem. Biophys. Res. Commun., 198(3), 967-972).
The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [125 _[]vfe_p e''7]-NKB and [3H]- Senktide specific binding to NK3 receptor in equilibrium conditions (IC50).
Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC50 values in the range 0.1-1000 nM. The NK3 -antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J. Pharmacol., 101, 996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991, Eur. J. Pharmacol., 199, 9-14) and human NK3 receptors-mediated Ca " " mobilization (Mochizuki et al, 1994, J. Biol. Chem., 269, 9651-9658). Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean Kg value of 3-8 separate experiments, where Kg is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide. Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca ""1" mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.
The activity of the compounds of the present invention, as NK-2 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK-2 ligands, [125I]-NKA or [3H]-NKA, to human NK-2 receptors (Aharony et al, 1992, Neuropeptide, 23, 121-130).
The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [125jj_js KA and [3H]-NKA specific binding to NK2 receptor in equilibrium conditions (IC50).
Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC50 values in the range 0.5-1000 nM, such as 1-1000 nM. The NK-2-antagonist activity of the compounds of the present invention is determined by their ability to inhibit human NK-2 receptor-mediated Ca"^ mobilization (Mochizuki et al, 1994, J. Biol. Chem., 269, 9651-9658). Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca" " " mobilization induced by the agonist NKA. In this assay, the compounds of the present invention behave as antagonists.
The therapeutic potential of the compounds of the present invention in treating the conditions can be assessed using rodent disease models.
As stated above, the compounds of formula (I) are also considered to be useful as diagnostic tool. Accordingly, the invention includes a compound of formula (I) for use as diagnostic tools for assessing the degree to which neurokinin-3 and neurokinin-2 receptor activity (normal, overactivity or underactivity) is implicated in a patient's symptoms. Such use comprises the use of a compound of formula (I) as an antagonist of said activity, for example including but not restricted to tachykinin agonist-induced inositol phosphate turnover or electrophysiological activation, of a cell sample obtained from a patient. Comparison of such activity in the presence or absence of a compound of formula (I), will disclose the degree of NK-3 and NK-2 receptor involvement in the mediation of agonist effects in that tissue.
The following Descriptions illustrate the preparation of the intermediates, whereas the following Examples illustrate the preparation of the compounds of the invention.
Descriptions and Examples
DESCRIPTION A: 3-MethyI-2-phenyl-quinoline-4-carboxyIic acid methyl ester
30 g (114 mmol) of 3-methyl-2-phenyl-quinoline-4-carboxylic acid (CAS [43071-45-0]) were suspended in 250 ml of dry CH2C12; 20 ml (230 mmol) of oxalyl chloride dissolved in 120 ml of CH2C12 were added dropwise and the reaction mixture was stirred at room temperature for 30 min. Two drops of N,N-dimethylformamide (DMF) were added and the reaction was stirred for additional 30 min. The solvent was evaporated in vacuo to dryness, the residue was taken up with 100 ml of CH2C12 and 100 ml of MeOH, dissolved in 400 ml of CH C12, were added dropwise. After stirring for 18 h, the solvent was evaporated in vacuo to dryness, the residue was taken up with CH2C1 and washed with 1% NaHCO3; the organic layer was dried over Na SO4, filtered and evaporated in vacuo to dryness to yield 31.6 g of the title compound as a solid, which was used in the following reaction without further purification.
Cι8H15NO2
MW 277.31
MP = 73-75°C
IR (KBr) 3441, 3051, 2954, 1731, 1582, 1556 cm'1.
DESCRIPTION B : 3-BromomethyI-2-phenyl-quinoline-4-carboxylic acid methyl ester
10 g (36 mmol) of 3-methyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description A) were dissolved in 500 ml of CH3CN; 13 g (72 mmol) of N- bromosuccinimide were added and the reaction mixture was heated to reflux. After adding 1 g (4.1 mmol) of dibenzoylperoxide, the reaction was refluxed for 24 h; then additional 4 g (22.5 mmol) of N-bromosuccinimide and 0.5 g (2.0 mmol) of dibenzoylperoxide were added and the reaction was refluxed for 4 h. The solvent was evaporated in vacuo to dryness to yield 26.1 g of crude methyl 3-bromomethyl-2- phenylquinoline-4-carboxylate (theorical amount, 12.8 g) which was used in the following reaction without further purification.
CI 8H14BrNO2 MW = 356.23
DESCRIPTION 1 : S-ll^'JBipiperidinyl-l'-ylmethyl^-phenyl-quinoline^-carboxylic acid methyl ester
5 g (14 mmol) of 3-bromomethyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description B), 2.9 g, (15.4 mmol) of 90% 4-piperidinopiperidine (Aldrich), 2.7 ml (15.4 mmol) diisopropylethyl amine were dissolved in 100 ml of dry THF and the mixture was stirred for one night at 50°C. The solvent was concentrated, the residue was dissolved in methylene chloride, washed with water, and the organic phase was dried over MgSO4. After concentration of the solvent the residue was purified by flash chromatography over 160 g of silicagel (eluent CH2Cl2/MeOH/NH4OH : 95/5/0.5) affording 3.5 g (yield 56%) of the title compound as a white solid.
C28H33N3O2
MW = 443.59 δ (CDC13) : 1.29-2.02(12H); 2.25(1H); 2.47(4H); 2.78(2H); 3.66(2H); 4.05(3H); 7.38-
7.55(5Har); 7.58(lHar); 7.72(lHar); 7.88(lHar); 8.17(lHar)ppm.
DESCRIPTION 2 : S-fl^'lBipiperidinyl-l'-ylmethyl^-phenyl-quinoIine^-carboxylic acid dihydrochloride
3.5 g (7.9 mmol) of 3-[l,4']bipiperidinyl- -ylmethyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description 1) and 50 ml 6N HC1 are refluxed for 1.5 h. then concentrated to dryness. The residue is triturated in acetone. This process is re- applied twice to the solid thus obtained affording, after drying in vacuo 4.5 g of the title compound as a crude dihydrochloride used without further purification in the next step.
C27H3N3O2.2HCl
MW = 502.56 δ (DMSOd6): 1.16-2.29(1 OH); 2.62-3.38(8H); 4.46(2H); 5.77(lHexch with D20); 7.45-
8.30(9Har); 11.12 (lHexch with D20)ppm.
DESCRIPTION 3 : 2-PhenyI-3-(4-phenyl-piperidin-l-yImethyI)-quinoline-4- carboxylic acid methyl ester
5.4 g of crude 3-bromomethyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description B) were dissolved, under nitrogen atmosphere, in 30 ml of dry THF. The solution was cooled to 10 °C and 4.0 g (24.8 mmol) of 4-phenylpiperidine, dissolved in 5 ml of THF, were added dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. Salts were filtered off and the filtrate was evaporated in vacuo to dryness, taken up with 2 N HC1 and washed with EtOAc; the aqueous layer was basified with 10% NaOH and extracted with CH2C12. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to dryness to obtain a crude material which was purified by gradient flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/hexane 10:90 containing 0.5 % NH4OH (28%) as starting eluent and a mixture of EtOAc/hexane 15:85 containing 0.5 % NH4OH (28%) as final eluent. 3.0 g of the title compound were recovered as an off- white solid.
C29H28N2O2
MW = 436.56
IR: (KBr) 3440, 3062, 2945, 1731, 1577, 1555 cm'1. DESCRIPTION 4: 2-Phenyl-3-(4-phenyl-piperidin-l-ylmethyl)-quinoIine-4- carboxylic acid hydrochloride
3.0 g (6.87 mmol) of 2-phenyl-3-(4-phenyl-piperidin-l-ylmethyl)-quinoline-4-carboxylic acid methyl ester (compound of Description 3) were dissolved in 100 ml of 6 N HC1 and refluxed for 1 h. Evaporation to dryness afforded 3.5 g of crude title compound, which was used in the following reaction without further purification.
C28H26N2O2.HCl
MW = 459.00
MP = 175-178°C
IR: (KBr) 3385, 3062, 2495, 1973, 1718, 1630 cm'1.
DESCRIPTION 5: 3-(4-Isopropyl-piperazin-l-ylmethyl)-2-phenyl-quinoline-4- carboxylic acid methyl ester
7.8 g of crude 3-bromomethyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description B) were dissolved, under nitrogen atmosphere, in 130 ml of dry THF. The solution was cooled to 10 °C and 2.8 g (21.6 mmol) of 1- isopropylpiperazine, dissolved in 20 ml of THF, were added dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. Salts were filtered off and the filtrate was evaporated in vacuo to dryness, taken up with 2 N HC1 and washed with EtOAc; the aqueous layer was basified with 10% NaOH and extracted with CH2C12. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to dryness to obtain a crude material which was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of Et2O/z'Pr2O 70:30 containing 0.3 % NH4OH (28%). 3.8 g of the title compound were recovered as a yellow solid.
C25H29N3O2
MW = 403.54
IR: (KBr) 3441, 3065, 2946, 1731, 1580, 1555 cm"1.
DESCRIPTION 6: 3-(4-Isopropyl-piperazin-l-ylmethyl)-2-phenyI-quinoline-4- carboxylic acid dihydrochloride
3.8 g (9.42 mmol) of 3-(4-isopropyl-piperazin-l-ylmethyl)-2-phenyl-quinoline-4- carboxylic acid methyl ester (compound of Description 5) were dissolved in 100 ml of 6 N HC1 and refluxed for 4 h. Evaporation to dryness afforded 4.0 g of crude title compound, which was used in the following reaction without further purification.
C24H27N3O2.2HCl .. MW = 389.50 MP = 177-180°C IR: (KBr) 3408, 2928, 2666, 1716, 1632 cm'1.
DESCRIPTION 7: (S)-l-Cyclohexyl-propylamine hydrochloride
2.0 g (14.8 mmol) of (S)-l-phenyl-propylamine were dissolved in 250 ml of a 4% solution of citric acid in H2O. 0.6 g of 20% Pd(OH)2/C were added and the reaction mixture was hydrogenated in a steel autoclave at 50 bar and 60 °C for 24 h. The catalyst was filtered off, the filtrate was evaporated and the residue was taken up with 40% NaOH and extracted several times with H O. The combined organic layers were dried over Na2SO4 and acidified with HCl/Et2O. Evaporation to dryness afforded 0.3 g of the title compound as a solid.
C9H19N.HC1 MW = 389.50
DESCRIPTION 8 : 3-(4-Fmoc-piperazin-l-ylmethyI)-2-phenyl-quinoline-4- carboxylic acid methyl ester
6.6 g (18.5 mmol) of 3-bromomethyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description B) were reacted with 6.8 g (20 mmol) of Fmoc piperazine in 150 ml of THF following the procedure used in Description 3 and afforded 7.5 g (yield : 69%) of the title compound.
C37H33N3O4
MW = 583.68
'H NMR δ(DMSOd6) : 1.99(4H); 3.10(4H); 3.62(2H); 3.97(3H); 4.20(1H); 4.42(2H);
7.18-7.40(4Har); 7.45-7.92(12Har); 8.09(1 Har)ppm.
DESCRIPTION 9 : 3-(4-Fmoc-piperazin-l-ylmethyI)-2-phenyl-quinoline-4- carboxylic acid hydrochloride
7.5 g (13 mmol) of the ester of Description 8 are hydrolysed with 6 N aqueous hydrochloric acid following the procedure used in Description 4 affording 9.5 g of crude title compound which was used without purification in the next step.
Figure imgf000034_0001
lH NMR δ(DMSOd6) : 2.50(4H); 3.32(4H); 4.22(2H); 4.23(1H); 4.35(2H); 6.50(lHexch with D2O); 7.22-7.88(14Har); 7.98(lHar); 8.17(2Har)ppm.
DESCRIPTION 10 : 3-(4-Fmoc-piperazin-l-ylmethyl)-2-phenyl-quinoline-4- carboxylic acid ((S)-l-phenyl-propyl)-amide
5.35 g (8.3 mmol) of crude acid of Description 9 were condensed on 1.7 ml (12.5 mmol) of (S)-l-phenyl-propylamine following the procedure of Example 2 affording, after flash chromatography on silica gel, 3.2 g (56%) of the title compound.
C45H42N4O3 MW = 686.86
Η NMR δ(DMSOd6) : 0.94(3H); 1.40-2.18(6H); 2.57-3.13(4H); 3.50(2H); 4.21(1H); 4.34(2H); 5.08(1H); 7.09-7.98(2 lHar); 8.03(lHar): 9.12(lHexch with D2O)ppm.
DESCRIPTION 11 : 3-(4-Fmoc-piperazin-l-yImethyl)-2-phenyl-quinoline-4- carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide
4.75 g (8.3 mmol) of crude acid of Description 9 were condensed on 1.65 ml (11 mmol) of (S)-l-cyclohexyl-ethylamine following the procedure of Example 2 affording, after flash chromatography on silica gel, 2.2 g (yield 43.9%) of the title compound.
C44H46N4O3
MW = 678.87
Η NMR δ(DMSOd6) : 0.95(3H); 1.68-4.00(21H); 2.60(3H); 5.08(1H); 7.22-8.24(13Har);
8.1 l(lHar); 9.32(lHexch with D2O); 10.82(2Hexch with D2O)ppm.
DESCRIPTION 12 : 3-(4-Fmoc-piperazin-l-ylmethyI)-2-phenyl-quinoline-4- carboxylic acid ((S)-2-methyl-l-phenyl-propyl)-amide
6.95 g (10.8 mmol) of crude acid of Description 9 were condensed on 2 g (13.5 mmol) of (S)-2-methyl-l -phenyl propylamine following the procedure of Example 2 affording, after flash chromatography on silica gel, 5.4 g (yield 71%) of the title compound.
C46H44N4O3
MW = 700.86
1H NMR δ(CDCl3) : 0.96(3H); 1.18(3H); 1.56-2.98(4H); 2.28(1H); 3.04(4H); 3.53(2H);
4.20(1H); 4.35(2H); 5.17(1H); 7.18-7.63(18Har); 7.74(3Har); 7.97(lHexch with D2O);
8.14(lHar)ppm.
DESCRIPTION 13 : 2-Phenyl-3-piperazin-l-ylmethyl-quinoIine-4-carboxyIic acid ((S)-2-methyI-l-phenyl-propyl)-amide
5.4 g (7.7 mmol) of the Fmoc derivative of Description 12 was reacted with 1.25 ml of piperidine in 200 ml acetonitrile, at room temperature for one night. The reaction mixture is concentrated to dryness and the residue was purified by flash chromatography on silicagel (eluant: CH2Cl2/CH3OH/NH4OH ; 90/10/2), affording 2.55 g (yield 69.3%) of the title compound.
C3ιH34N4O MW = 478.64
Η NMR δ(DMSOd6) : 0.79(3H); 1.06(3H); 1.49-2.55(9H); 3.45(2H and lHexch with D2O); 4.88(1H); 7.12-8.10(14Har); 9.16(lHexch with D2O)ppm.
DESCRIPTION 14 : 2-Phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide
2.75 g (41 mmol) of the Fmoc protected derivative of Description 12 afforded by applying the procedure of Description 13, 1.14 g (yield 60%) of the title compound. C3oH32N4O MW = 464.61
Η NMR δ(DMSOd6) : 0.94(3H); 1.57-2.08(6H); 2.31(4H); 3.36(2H and lHexch with D2O); 5.07(1H); 7.13-7.94(13Har); 8.01(lHar); 9.17(lHexch with D2O)ppm.
DESCRIPTION 15 : 3-[4-(l-Cyanoimino-l-methylsulfanyl-methyI)-piperazin-l- ylmethyI]-2-phenyI-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide
0.5 g (1.1 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)-l- cyclohexyl-ethyl)-amide (compound of Example 34) and 0.16 g (1.1 mmol) of dimethyl N-cyanodithioiminocarbonate (Aldrich) were heated at reflux for 6 h in a mixture of 2.2 ml of DMF and 8.8 ml of EtOH.
The solvent was concentrated and the residue purified by flash chromatography on silicagel (CH2Cl2/MeOH : 98/2) affording 0.56g (yield 91.8%) of the title compound which was used without purification in the following step.
C33H34N6OS
MW = 562.74
1H NMR δ(CDCl3) : 1.00-1.39(5H); 1.24(3H); 1.48(1H); 1.63-1.96(5H); 2.25(4H);
2.69(3H); 3.57(4H); 3.72(2H); 4.25(1H); 6.42(lHexch with D2O; 7.38-7.55(5Har);
7.60(lHar); 7.75(lHar); 7.95(lHar); 8.14(lHar)ppm.
DESCRIPTION 16 : 3-[4-(l-Methanesulfonylimino-l-methylsulfanyl-methyl)- piperazin-l-ylmethyl]-2-phenyl-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)- a ide
0.48 g (1.05 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)- 1 -cyclohexyl-ethyl)-amide (compound of Example 34) and 0.21 g (1.05 mmol) of carbonimidodithioic acid, (methylsulfonyl)-dimethyl ester (RN 13068-10-5) were heated at reflux for 5 h in a mixture of 2 ml of DMF and 8 ml of EtOH. The solvent was concentrated and the residue purified by flash chromatography on silicagel (CH Cl2/MeOH : 97/3) affording 0.52g of crude title compound which was used without purification in the following step.
C33H37N4O3S2
MW = 615.82
Η NMR δ(CDCl3) : 0.95-1.38(5H); 1.28(3H); 1.48(1H); 1.62-1.94(5H); 2.28(4H); 2.47(3H); 3.01(3H); 3.54(4H); 3.59(2H); 4.25(1H); 6.52(lHexch with D2O); 7.36- 7.53(5Har); 7.59(lHar); 7.75(lHar); 7.95(lHar); 8.14(lHar)ppm.
DESCRIPTION 17 : 4-[4-((S)-l-Cyclohexyl-ethylcarbamoyl)-2-phenyl-quinolin-3- ylmethyl]-N-methyl-piperazine-l-carboximidothioic acid methyl ester
0.05 g (0.95 mmol) of 3-(4-methylthiocarbamoyl-piperazin-l-ylmethyl)-2-phenyl- quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide (compound of Example 75) was suspended in 5 ml acetone and 0.41 g (2.85 mmol) methyl iodide was added. After 4h stirring at room temperature the mixture became clear. The solvent was concentrated and the residue triturated with di-ethyl ether affording, after filtration and drying, 0.63 g of the hydroiodide salt of the title compound. This compound was used without further purification in the next step.
C33H37N5OS MW = 551.76
'H NMR δ(DMSOd6) : 0.92-1.36(5H); 1.75(3H); 1.47(1H); 1.58-1.92(5H); 2.24(4H); 2.46(3H); 3.05(3H); 3.36(4H); 3.63(2H); 4.02(1H); 7.36-7.91(8Har); 8.04(lHar); 8.55(lHexch with D2O)ppm.
DESCRIPTION 18 : 3-(4-Oxo-piperidin-l-ylmethyl)-2-phenyl-quinoline-4-carboxyIic acid ((S)-l-phenyl-propyI)-amide
Starting from 3-bromomethyl-2-phenylquinoline-4-carboxylic acid methyl ester (compound of Description B) and 4-oxopiperidine, following the procedure of description 1, then applying procedures analogous to those described in description 2 and example 2 afforded the title compound after purification on silicagel (EtO Ac/Heptane : 1/1).
Figure imgf000037_0001
MW = 477.60
Η NMR δ(DMSOd6) : 0.83(3H); 1.57-2.30(8H); 2.45(2H); 3.34-3.98(2H); 5.08(1H); 7.12-8.18(14Har); 9.21(lHexch with D2O)ppm.
DESCRIPTION 19 : 4-tert-ButylsuIfamoyI-piperazine-l-carboxylic acid tert-butyl ester
6.1 g (32.62mmol) of piperazine-1 -carboxylic acid tert-butyl ester (RN 76535-74-5) were dissolved in 150 ml of CH2C12 and 4.5 g (32.6 mmol) of K2CO3 were added. The mixture was cooled to 0°C and 5.6 g (32.62 mmol) of tert-butyl-sulfamoylchloride (prepared according to Catt, J.D. JOC, 1974, 39, 566-8) dissolved in 50 ml of CH2C12 were added dropwise and the reaction mixture was stirred at room temperature for 2 h. 50 ml of water were added, the two phase separated in a separatory funnel and the aqueous phase extracted with CH2C12. The organic phases were collected, dried over Na SO4 and evaporated in vacuo to dryness to yield 4.6 g of the title compound as a yellow solid
Figure imgf000037_0002
MW = 321.43 IR: (KBr) 3273, 2971, 1701, 1364, 1137, 1023, 934, 768 cm'1.
DESCRIPTION 20 : 4-Dimethylsulfamoyl-piperazine-l-carboxylic acid tert-butyl ester
Prepared as described in Description 19 from 10.38 g (55.7 mmol) of piperazine-1 - carboxylic acid tert-butyl ester (RN 76535-74-5), 7.7 g (55.7 mmol) of K2CO3 and 8g (55.7 mmol) of dimethyl-sulfamoylchloride 15.2 g of the title compound were obtained as a yellow solid
Figure imgf000038_0001
MW = 293.39
IR: (KBr) 2979, 2865, 1687, 1142, 952, 752 cm'1
DESCRIPTION 21 : Piperazine-1-sulfonic acid tørt-butylamide
4.6 g (14.3 mmol) of 4-tert-butylsulfamoyl-piperazine-l -carboxylic acid tert-butyl ester (compound of Description 19) were dissolved in 10 ml of CH2C12 and 50 ml of 30% ethereal HC1 were added. The solution was stirred at room temperature for 2 h. The solvent was evaporated in vacuo to dryness yielding 1.5 g of the title compound as a white solid
C8H19N3O2S
MW = 221.32
IR: (KBr) 3207, 2730, 1591, 1326, 1143, 1001, 917, 720, 631 cm'1
DESCRIPTION 22 : Piperazine-1-sulfonic acid dimethylamide
13 g (44.31 mmol) of 4-dimethylsulfamoyl-piperazine-l -carboxylic acid tert-butyl ester (compound of Description 20) were dissolved in 100 ml of CH2Cl2 and 20 ml of 30% ethereal HC1 were added. The solution was stirred at room temperature for 2 h. The solvent was evaporated in vacuo to dryness yielding 9.2 g of the title compound as a white solid
C6H15N3O2S
MW = 193.27
IR: (KBr) 2786, 1688, 1356, 1152, 1037, 942, 867, 737,677 cm'1
DESCRIPTION 23 : 3-(4-terf-ButyIsulfamoyl-piperazin-l-ylmethyl)-2-phenyl- quinoline-4-carboxylic acid methyl ester
1.5 g (6.78 mmol) of piperazine-1 -sulfonic acid tert-butylamide (compound of Description 21) and 0.94 g (6.78 mmol) of K2CO3 were suspended in 70 ml of CH3CN. 2.42 g (6.78 mmol) of 3-bromomethyl-2-phenylquinoline-4-carboxylic acid methyl ester (compound of Description B) were dissolved in 30 ml of CH3CN and the solution was added to the previous suspension. The resulting mixture was stirred at room temperature for 4h. The solvent was evaporated in vacuo to dryness, the residue was taken up with 6N HC1 and washed with EtOAc. The aqueous phase was basified with 1 N NaOH and extracted with EtOAc. The organic phase was dried over Na2SO4 and evaporated to dryness to yield a 3.0 of crude title compound used without further purification
C26H32N4O4S MW = 496.63 IR: (KBr) 3280, 2974, 1734, 1575, 1555, 1444, 1220, 1146, 940 764 cm'1
DESCRIPTION 24 : 3-(4-Dimethylsulfamoyl-piperazin-l-ylmethyl)-2-phenyl- quinoline-4-carboxylic acid methyl ester
1.6 g (8.24 mmol) of piperazine-1 -sulfonic acid dimethylamide (compound of Description 22) and 1.16 g (8.42 mmol) of K2CO3 were suspended in 70 ml of CH3CN. 3.0 g (8.42 mmol) of 3-bromomethyl-2-phenylquinoline-4-carboxylic acid methyl ester (compound of Description B) were dissolved in 30 ml of CH3CN and the solution was added to the previous suspension. The resulting mixture was stirred at room temperature for 4h. The solvent was evaporated in vacuo to dryness, the residue was taken up with 6N HC1 and washed with EtOAc. The aqueous phase was basified with 1 N NaOH and extracted with EtOAc. The organic phase was dried over Na2SO4 and evaporated to dryness to yield a crude material which was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/hexane 3:7 as eluent. After evaporation of the solvent, 3.0 g of the title compound as a yellow solid were obtained.
C24H28N4O4S MW = 468.58 IR: (KBr) 2938, 1736, 1574, 1552, 1452, 1244, 1156, 942 748 cm"1
DESCRIPTION 25 : 2-Phenyl-3-(4-sulfamoyl-piperazin-l-ylmethyl)-quinoIine-4- carboxylic acid
3.0 g (6.04 mmol) of 3-(4-tert-butylsulfamoyl-piperazin-l-ylmethyl)-2-phenyl-quinoline- 4-carboxylic acid methyl ester (compound of Description 23) were suspended in 50 ml of 6N HC1 and the mixture was refluxed for 4h. The solvent was evaporated in vacuo to dryness. For three times the residue was treated with Et2O and the solvent was evaporated to dryness to yield 3.0 of crude title compound used without further purification
C21H22N4O4S
MW = 426.44
IR: (KBr) 3281, 2974, 1734, 1556, 1221, 1146, 1056, 941, 765 cm"1
DESCRIPTION 26 : 3-(4-DimethyIsulfamoyl-piperazin-l-ylmethyl)-2-phenyl- quinoline-4-carboxylic acid
3.0 g (6.40 mmol) of 3-(4-dimethylsulfamoyl-piperazin-l-ylmethyl)-2-phenyl-quinoline- 4-carboxylic acid methyl ester (compound of Description 24) were suspended in 50 ml of 6N HC1 and the mixture was refluxed for 4h. The solvent was evaporated in vacuo to dryness. After trituration of the residue with Me2CO, 1.4 g of the title compound were recovered as a pale yellow solid used without further purification.
C23H26N4O4S MW = 454.55
IR: (KBr) 3427, 2658, 1726, 1632, 1581, 1452, 1344, 1151, 932 745 cm'1
DESCRIPTION 27:"7-Methoxy-3-methyl-2-phenyl-quinoline-4-carboxylic acid methyl ester
16 g (54.5 mmol) of 7-methoxy-3-methyl-2-phenyl-quinoline-4-carboxylic acid (prepared analogously to starting material of Description A) were suspended in 400 ml of dry CH2C12 and 9.52 ml (126.93 mmol) of oxalyl chloride were added dropwise. Two drops of N,N-dimethylformamide (DMF) were added and the reaction mixture was stirred for 3h at room temperature. The solvent was evaporated in vacuo to dryness, the residue was taken up with 150 ml of CH2C12 and quickly dropped in a solution of 200 ml of MeOH and 200 ml of CH2C12. After stirring for 1 h, the solvent was evaporated in vacuo to dryness, the residue was taken up with EtOAc and washed with 1% NaHCO3; the organic layer was dried over Na2SO4, filtered and evaporated in vacuo to dryness. After trituration of the residue with Et2O, 19 g of the title compound were recovered as a dark powder used without further purification.
C19H17NO3
MW = 307.35
IR (KBr) 3067, 2947, 1918, 1729, 1634, 1581, 1246, 846 cm"1.
DESCRIPTION 28 : 3-[l,4']Bipiperidinyl-r-ylmethyl-8-bromo-7-methoxy-2-phenyl- quinoline-4-carboxylic acid methyl ester
Prepared as described in Description B and Description 1 from 4.7 g (15.3 mmol) of 7- methoxy-3-methyl-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description 27), 5.5 g (30.6 mmol) of N-bromosuccinimide, 0.5 g (2.05 mmol) of dibenzoylperoxide, 3.85 g (23 mmol) of 4-piperidinopiperidine and 3.18 g ( 23.0 mmol) of K2CO3, by stirring in CH3CN at room temperature for 4h. 6.2 g of the title compound were obtained.
C29H34BrN3O3
MW = 552.51
IR (KBr) 3370, 2938, 1712, 1612, 1352, 1268, 1174, 704 cm"1.
DESCRIPTION 29 : 3-[l,4']Bipiperidinyl-l'-yImethyl-8-bromo-7-methoxy-2-phenyl- quinoline-4-carboxylic acid hydrochloride
Prepared as described in Description 4 from 6.0 g (10.9 mmol) of 3-[l ,4']bipiperidinyl-l'- ylmethyl-8-bromo-7-methoxy-2-phenyl-quinoline-4-carboxylic acid methyl ester (compound of Description 28) and 50 ml of 6 N HC1 yielding 4.7 g of a slightly brown powder. C28H32BrN3θ3.HCl
MW = 574.94
IR: (KBr) 3453, 2939, 2532, 1714, 1607, 1598, 1271, 1072, 960, 779, 705, cm'1.
DESCRIPTION 30 : 3-[l,4']Bipiperidinyl-l'-ylmethyl-8-chIoro-7-methoxy-2-phenyl- quinoline-4-carboxylic acid methyl ester
Prepared as described in Description B and Description 1 from 9.0 g (29.3 mmol) of 7- methoxy-3-methyl-2-phenyl-quinoline-4-carboxylic acid methyl ester hydrochloride (compound of Description 27 • HC1), 10.4 g (58.6 mmol) of N-bromosuccinimide, 1.0 g (4.10 mmol) of dibenzoylperoxide 9.9 g (58.6 mmol) of 4-piperidinopiperidine and 3.18 g ( 23.0 mmol) of K2CO3. Purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/MeOH 9:1 containing 0.1 % NH4OH (28%) affording 1.7 g of the title compound.
C29H34ClN3O3 MW = 508.06 IR (KBr) 2934, 1730, 1610, 1501, 1238, 1079, 774, 706 cm'1.
DESCRIPTION 31 : 3-[l,4']BipiperidinyI-l'-ylmethyl-8-chloro-7-hydroxy-2-phenyl- quinoline-4-carboxyIic acid dihydrobromide
1.5 g (3.0 mmol) of 3-[l,4']bipiperidinyl-l'-ylmethyl-8-chloro-7-methoxy-2-phenyl- quinoline-4-carboxylic acid methyl ester (compound of Description 30) were dissolved in 50 ml of 48% HBr and the solution was refluxed for 8h. The solvent was evaporated in vacuo to dryness yielding 2.2 g of the crude title compound as a dark powder used without further purification.
Figure imgf000041_0001
MW = 736.76
IR: (KBr) 2948, 1725, 1624, 1226, 959, 705 cm'1.
The following Examples illustrate the invention; Table 1 summarizes all the compounds of the Examples 1-95 and their analytical data; Table 2 describes NMR spectroscopic data of Examples 1-95 and Table 3 illustrates chemical names of compounds of Examples 1-95.
EXAMPLE 2: 2-Phenyl-3-(4-phenyl-piperidin-l-ylmethyl)-quinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide
2.5 g (5.0 mmol) of crude 2-phenyl-3-(4-phenyl-piperidin-l-ylmethyl)-quinoline-4- carboxylic acid hydrochloride (compound of Description 4) were dissolved in 50 ml of dry THF; 1.1 ml (7.8 mmol) of triethylamine (TEA) and 2.4 g (6.5 mmol) of O- benzotriazol- 1 -yl-N,N,N' ,N' -tetramethyluroniumhexafluoro-phosphate (HBTU) were added and the reaction mixture was cooled at 0 °C. 0.72 ml (5 mmol) of (S)-l-phenyl- propylamine, dissolved in 20 ml of dry CH2CI2, were added dropwise and the reaction mixture was stirred at room temperature for 24 h and at 50 °C for 2 h. The solvent was evaporated in vacuo to dryness and the residue was taken up with EtOAc and washed with H2O, 1 N NaOH and brine, dried over Na2SO4 and evaporated to dryness to yield a crude material which was purified by gradient flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/hexane 3:7 as starting eluent, and a mixture of EtOAc/hexane 4:6 as final eluent. After trituration with iPr2O, 1.0 g of the title compound were recovered as a pale yellow solid used without further purification.
C37H37N3θ
MW = 539.72
IR: (KBr) 3279, 3060, 3028, 2931, 1633, 1536, 1494, 757, 699 cm'1.
EXAMPLE 4 : 3-(4-Isopropyl-piperazin-l-ylmethyl)-2-phenyl-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide dihydrochloride
2.3 g (5.0 mmol) of crude 3-(4-isopropyl-piperazin-l-ylmethyl)-2-phenyl-quinoline-4- carboxylic acid dihydrochloride (compound of Description 6) were dissolved in 200 ml of a 1:1 mixture of CH2C12/CH3CN; 2.0 ml (15 mmol) of triethylamine (TEA) and 2.5 g (6.5 mmol) of O-benzotriazol- 1 -yl-N,N,N' ,N' -tetramethyluroniumhexafluorophosphate (HBTU) were added and the reaction mixture was cooled at 0 °C. 0.74 ml (5 mmol) of (S)-l-cyclohexyl-ethylamine, dissolved in 10 ml of dry CH2CI2, were added dropwise and the reaction mixture was stirred at room temperature for 24 h. The solvent was evaporated in vacuo to dryness and the residue was taken up with EtOAc and washed with H2O, 1 N NaOH and brine, dried over Na2SO4 and evaporated to dryness to yield a crude material which was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of CH2Cl2/MeOH 95:5 containing 0.5 % NH4OH (28%). The residue was dissolved in acetone and acidified with HCl/Et2θ; the precipitate so formed was recovered by suction filtration to yield 0.9 g of the title compound as a yellow solid.
C32H42N4O.2HCl
MW = 571.64
IR: (KBr) 3411 ; 2927; 2851; 2667; 1650; 1546 cm"1.
EXAMPLE 13: 3-[l,4']Bipiperidinyl- -ylmethyl-2-phenyl-quinoIine-4-carboxylic acid ((S)-l-cycIohexyl-ethyl)-amide dihydrochloride
4.0 g (8.0 mmol) of crude 3-[l,4']bipiperidinyl-l'-ylmethyl-2-phenyl-quinoline-4- carboxylic acid dihydrochloride (compound of Description 2) were dissolved in 300 ml of a 1 : 1 mixture of CH2CI2/CH3CN; 3.4 ml (24.6 mmol) of triethylamine (TEA) and 4.0 g (10.7 mmol) of O-benzotriazol-l-yl-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU) were added and the reaction mixture was cooled ot 0 °C. 1.22 ml (8.2 mmol) of (S) 1-cyclohexylethylamine, dissolved in 10 ml of dry CH2CI2, were added dropwise and the reaction mixture was stirred at room temperature for 24 h. Additional 2.0 g (5.3 mmol) of HBTU and 2.0 ml (13.4 mmol) of (S)-l-cyclohexyl-ethylamine were added and the reaction mixture was heated to 40 °C for 8 h. The solvent was evaporated in vacuo to dryness and the residue was taken up with EtOAc and washed with H2O, 1 N NaOH and brine, dried over Na2SO4 and evaporated to dryness to yield a crude material which was purified by flash column cromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/MeOH 95:5 containing 0.5 % NH4OH (28%). The residue was dissolved in acetone and acidified with HCl/Et2U; the precipitate so formed was recovered by suction filtration to yield 3.2 g of title compound as a pale yellow solid.
C35H46N4O.2HCl
MW =611.70
IR: (KBr) 3422, 2928, 2852, 2659, 1647, 1546 cm"1.
EXAMPLE 34 : 2-PhenyI-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)-l- cyclohexyl-ethyl)-amide
Synthesised starting from the compound of Description 11 and following the procedure of Description 13.
C29H36N4O MW = 456.63
EXAMPLE 47 : 3-[4-(3-Diethylamino-propanoyl)-piperazin-l-ylmethyl]-2-phenyl- quinoline-4-carboxylic acid ((S)-l-cyclohexyI-ethyl)-amide
0.4 g (0.88 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)- l-cyclohexyl-ethyl)-amide (compound of Example 34), 0.5 g (1.3 mmol) of HBTU, 360 microliters (2.5 mmol) of triethyl amine and 240 mg of 3-diethylaminopropionic acid were dissolved in 10 ml of anhydrous THF and were stirred 16 hours at room temperature. The solvent was concentrated to dryness and the residue was dissolved in 20 ml of EtOAc and washed with water then with 0.5 N aqueous NaOH and again with water. The organic phase was dried over MgSO4, concentrated to dryness. The residue was purified by flash chromatography on silicagel (C^C^/MeOH : 90/10). The fractions containing the desired compound were concentrated and the residue was crystallised from di-isopropyl ether affording 250 mg (yield 48.7%) of the title compound as white crystals.
Figure imgf000043_0001
MW = 583.82
EXAMPLE 53 : ({4-[4-((S)-l-Cyclohexyl-ethylcarbamoyI)-2-phenyI-quinolin-3- ylmethyl]-piperazin-l-yl}-dimethylamino-methylene)-dimethyl-ammonium hexafluorophosphate 50 mg (0.11 mmol) of the piperazine of Example 34 were reacted with 62 mg (0.16 mmol) of HBTU and 18 mg (0.17 mmol) of triethylamine in a mixture of 1.2 ml of anhydrous THF and 1 ml of CH2C12. This mixture was stirred 48h at room temperature, then concentrated to-dryness. The residue was dissolved in 1 ml of water and 1 ml of ethyl acetate. The aqueous phase was extracted twice with EtOAc, washed twice with water, dried over MgSO4, concentrated to dryness. The residue was purified by flash chromatography on silicagel (CH2Cl2/MeOH : 95/5) to afford 43 mg of the title compound as a white solid (yield 55.8%).
C3 H47N6O.PF6 MW = 700.75
EXAMPLE 55 : 3-(4-Amino-piperidin-l-ylmethyl)-2-phenyl-quinoline-4-carboxyIic acid ((S)-l-phenyl-propyl)-amide
0.477 g (l mmol) of 3-(4-oxo-piperidin-l-ylmethyl)-2-phenyl-quinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide (compound of Description 18), 0.462 g (6 mmol) of ammonium acetate were dissolved in 10 ml of methanol and stirred at room temperature for 1 h. Then 0.08 g of sodium cyanoborohydride were added and the mixture was stirred one night at room temperature. The reaction mixture was poured in 50 ml of water and the formed precipitate was filtered off. The aqueous phase was extracted with methylene chloride. The collected solid was dissolved in methylene chloride, both organic phases merged, washed with water, dried over MgSO4, concentrated to dryness. The residue was purified by micro flash chromatography on silicagel (C^C /MeOH/NH^OH : 90/10/1) to afford 47 mg of the title compound as a white solid (yield ca 10 %).
C31H34N4O MW = 478.64
EXAMPLE 66 : S-ll^'lBipiperidinyl-l'-ylmethyl-S-bromo-T-methoxy-Z-phenyl- quinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide
Prepared as described in Exemple 2 from 2 g (3.7 mmol) of 3-[l,4']bipiperidinyl-l'- ylmethyl-8-bromo-7-methoxy-2-phenyl-quinoline-4-carboxylic acid (compound of Description 29), 1.55 ml (11.1 mmol) of triethylamine (TEA) 1.82 g (4.8 mmol) of O- benzotriazol-l-yl-N,N,N\N'-tettamethyluroniumhexa-fluorophosphate (HBTU) and 0.75 g (5.5 mmol) of (S)-l-phenyl-propylamine The crude material was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/MeOH 95:5 containing 0.05 % N^OH (28%) affording 0.4 g of title compound.After trituration with iPr2O, 0.3 g of the title compound were recovered as a pale yellow solid.
C37H43BrN4O2
MW = 655,68
IR: (KBr) 3278, 2936, 1641, 1276, 1073, 845, 702cm"1. EXAMPLE 67 : 3-[l,4']Bipiperidinyl-r-ylmethyl-7-methoxy-2-phenyl-quinoline-4- carboxylic acid ((S)-l-phenyI-propyl)-amide hydrochloride
0.2 g (0.31 mmol) of 3-[l,4']Bipiperidinyl-r-ylmethyl-8-bromo-7-methoxy-2-phenyl- quinoline-4-carboxylic acid ((S)- 1 -phenyl-propyl)-amide (compound of Example 66) and 0.43 ml (0.31 mmol) of TEA were dissolved in 100 ml of EtOH. 20 mg of 10% Palladium on charcoal were added under nitrogen atmosphere and the mixture was hydrogenated at 1 psi for 3h. The catalyst was filtered off, the solvent was evaporated in vacuo to dryness and the residue was purified by gradient flash column chromatography on 230-400 mesh silica gel, utilising EtOAc containing 0.05 % NH4OH (28%) as starting eluent, and a mixture of EtOAc/MeOH 95:5 containing 0.05 % N UOH (28%) as final eluent. The residue was dissolved in acetone and acidified with HCl/Et2O; the precipitate so formed was recovered by suction filtration to yield 0.1 g of the title compound as a pale yellow solid.
C37H44N4O2
MW = 576.78
IR: (KBr) 3239, 2943, 2530, 1619, 1534, 1222, 1027, 844, 703 cm"1.
EXAMPLE 72 : 3-[4-(3,4-Dioxo-2-pyrroIidin-l-yl-cyclobut-l-enyI)-piperazin-l- ylmethyl]-2-phenyl-quinoline-4-carboxy lie acid ((S)-l-cyclohexyl-ethyl)-amide
0.25 g (0.55 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)- 1 -cyclohexyl-ethyl)-amide (compound of Example 34) and 0.124 g (0.55 mmol) of 3,4- di-N-butoxy-3-cyclobuten-l,2-dione (Aldrich) were stirred in 3 ml of ethanol at room temperature for 7 h. Then, 0.15 g (2.2 mmol) of pyrrolidine was added and stirring was continued for one night. The mixture was concentrated in vacuo and the residue was purified by flash chromatography on silicagel (CH2Cl2/MeOH : 98/2). After concentration of the desired fractions, the residue was crystallised from di-isopropyl ether. The solid obtained was purified again by chromatography on silicagel (EtOAc as eluent). After concentration of the desired fractions the residue was re-crystallised from di-isopropyl ether to afford 0.180 g (yield 54%) of the title compound as white crystals.
C37H43N5O3 MW = 605.78
EXAMPLE 75 : 3-(4-Methylthiocarbamoyl-piperazin-l-ylmethyl)-2-phenyl- quinoline-4-carboxylic acid ((S)-l-cycIohexyl-ethyl)-amide
0.4 g (0.87 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)- 1 -cyclohexyl-ethyl)-amide (compound of Example 34) were dissolved in 10 ml of methylene chloride and 0.09 g methylisothiocyanate were added. The mixture was stirred for 5 h at room temperature and the solvent was concentrated in vacuo and the residue was purified by flash chromatography on silicagel (EtO Ac/heptane : 95/5) to afford 0.43 g (yield 92%) of the title compound as white crystals.
C31H39N5OS MW = 529.75 EXAMPLE 76 : 3-[4-(l-Cyanoimino-l-pyrroIidin-l-yl-methyl)-piperazin-l- ylmethyl]-2-phenyl-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide
0.25 g (0.45 mmol) of 3-[4-(l-cyanoimino-l-methylsulfanyl-methyl)-piperazin-l- ylmethyl]-2-phenyl-quinoline-4-carboxylic acid ((S)- 1 -cyclohexyl-ethyl)-amide (compound of Description 15) and 1.5 ml of pyrrolidine were heated to reflux for 2 h. The excess of pyrrolidine was removed in vacuo and the residue was purified by flash chromatography on silicagel (EtOAc/CH2Cl2 : 80/20). After concentration of the desired fractions the residue was crystallised from di-isopropyl ether to afford 0.195 g (yield 75%) of the title compound as white crystals.
C35H43N7O MW = 577.77
EXAMPLE 78 : 3-[4-(l-Methylimino-l-pyrrolidin-l-yl-methyl)-piperazin-l- ylmethyl]-2-phenyl-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide
0.2 g (ca 0.3 mmol) of the crude salt of Description 17 was dissolved in 10 ml of acetonitrile and 1 g of pyrrolidine and 1.5 g of KF were added. The mixture was refluxed for one night. After prolonged concentration under vacuum, the residue was dissolved in methylene chloride and the solid filtered off and discarded. The solution was concentrated and the residue purified by flash chromatography on silicagel (EtOAc/MeOH/NH4OH : 90/10/1). After concentration of the desired fractions, the residue was crystallised from diethyl ether to afford 0.120 g (yield 71%) of the title compound as a white amorphous solid.
MW = 566.79
EXAMPLE 82 : 3-(4-Carbamimidoyl-piperazin-l-ylmethyl)-2-phenyl-quinoline-4- carboxylic acid ((S)-l-cyclohexyl-ethyI)-amide sesqui-p-toluenesulphonate
0.3 g (0.66 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)- 1 -cyclohexyl-ethyl)-amide (compound of Example 34), 0.313 g (0.94 mmol) of benzotriazole-1-carboxamidinium -toluenesulphonate (reagent described in Synthetic Communications, 1995, 25 (8), 1173-1186), 0.167 ml (0.94 mmol) of diisopropylethylamine were stirred for 3 days. Addition of diethyl ether led to the formation of a precipitate which was further triturated with ethyl ether. The white solid was purified by two successive flash chromatographies on silicagel, eluting first with CH2Cl2/MeOH : 90/10, then with CH2Cl2/MeOH/NH4OH : 90/10/1. Concentration of the desired fractions gave a solid which was triturated with diethyl ether to afford 0.225 g of the title compound as a salt ofp-toluenesulfonic acid. Analysis of the NMR spectra suggested the occurrence of 1.6 equivalent of acid for one molecule of parent compound (in Table 2, the NMR refers to the parent compound).
C30H38N6O-1.5C7H8O3S MW = 757.00 EXAMPLE 84 : 3-[4-(l-Methanesulfonylimino-l-pyrroIidin-l-yl-methyl)-piperazin- l-ylmethyI]-2-phenyl-quinoline-4-carboxylic acid ((S)-l-cyclohexyl-ethyl)-amide
0.46 g (0.76 mmol) of crude 3-[4-(l-methanesulfonylimino-l-methylsulfanyl-methyl)- piperazin- 1 -ylmethyl]-2-phenyl-quinoline-4-carboxylic acid ((S)- 1 -cyclohexyl-ethyl)- amide (compound of Description 16) and 5 ml of pyrrolidine were heated to reflux for 5 h. The excess of pyrrolidine was removed in vacuo and the residue was purified by flash chromatography on silicagel (CH2Cl2/MeOH : 97/3). After concentration of the desired fractions, the residue was crystallised in di-isopropyl ether to afford 0.310 g (yield 65%) of the title compound as white crystals.
C35H46N6O3S MW = 630.85
EXAMPLE 85 : 4-{4-[4-((S)-2-MethyI-l-phenyI-propylcarbamoyI)-2-phenyl- quinolin-3-ylmethyl]-piperazin-l-yl}-4-oxo-butyric acid
200 mg (0.42 mmol) of 2-phenyl-3-piperazin-l-ylmethyl-quinoline-4-carboxylic acid ((S)-l-phenyl-propyl)-amide (compound of Description 13) were dissolved in 5 ml acetone and 42 mg of succinic anhydride were added. The mixture was then refluxed for 10 hours. After cooling the mixture was diluted with 50 ml of CH2C12, washed three times with 30 ml water, dried over MgSO4, concentrated to dryness. The residue was purified by flash chromatography on silicagel (CH2Cl2/MeOH : 90/10) to afford 130 mg of the title compound as white crystals (yield 54%).
Figure imgf000047_0001
MW = 578.71
EXAMPLE 90 : 2-Phenyl-3-(4-sulfamoyl-piperazin-l-ylmethyl)-quinoline-4- carboxylic acid ((S)-l-phenyl-propyI)-amide
3.0 g (5.78 mmol) of crude 2-phenyl-3-(4-sulfamoyl-piperazin-l-ylmethyl)-quinoline-4- carboxylic acid (compound of Description 25) were dissolved in 150 ml of 1 :1 mixture of CH2CI2 and dry THF; 2.41 ml (17.34 mmol) of triethylamine (TEA) and 4.38 g (11.56 mmol) of O-benzotriazol-l-yl-N,N,N',N'-tetramethyl-uroniumhexafluorophosphate (HBTU) were added and the reaction mixture was cooled at 0 °C. 1.56 g (11.56 mmol) of (S)-l-phenyl-propylamine, dissolved in 20 ml of dry CH2CI2, were added dropwise and the reaction mixture was stirred at room temperature for 24 h and at 50 °C for 4 h. The solvent was evaporated in vacuo to dryness and the residue was taken up with EtOAc, washed with H2O and 1 N NaOH, dried over Na2SO4 and evaporated to dryness. The crude material was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/hexane 8:2. After trituration with z'P^O, 1.05 g of the title compound were recovered as a pale yellow solid.
Figure imgf000047_0002
MW = 543.69 IR: (KBr) 3270, 3060, 2967, 1959, 1644, 1537, 1492, 1455, 1354, 1163, 949, 764, 702 cm"1.
EXAMPLE 91 : 3-(4-DimethyIsulfamoyl-piperazin-l-ylmethyl)-2-phenyl-quinoline- 4-carboxylic acid ((S)-l-phenyl-propyI)-amide
1.4 g (2.85 mmol) of crude 3-(4-Dimethylsulfamoyl-piperazin-l-ylmethyl)-2-phenyl- quinoline-4-carboxylic acid (compound of Description 26) were dissolved in 100 ml of 1 :1 mixture of CH2C12 and dry THF; 1.19 ml (8.55 mmol) of triethylamine (TEA) and 2.16 g (5.70 mmol) of O-benzotriazol-l-yl-N,N,N',N'- tetramethyluroniumhexafluorophosphate (HBTU) were added and the reaction mixture was cooled at 0 °C. 0.77 g (5.70 mmol) of (S)-l-phenyl-propylamine, dissolved in 15 ml of dry CH2C1 , were added dropwise and the reaction mixture was stirred at room temperature for 24 h and at 50 °C for 4 h. The solvent was evaporated in vacuo to dryness and the residue was taken up with EtOAc and washed with H2O and 1 N NaOH, dried over Na2SO4 and evaporated to dryness to yield a crude material which was purified by flash column chromatography on 230-400 mesh silica gel, utilising a mixture of EtOAc/hexane 8:2. After trituration with z'Pr2O, 0.3 g of title compound were recovered as a white powder.
C32H37N5O3S
MW = 571.74
IR: (KBr) 3315, 3059, 2965, 2813, 1955, 1661, 1638, 1533, 1491, 1455, 1349, 1152, 947,
748, 702 cm"1.
Figure imgf000049_0001
R3 = Ph
Figure imgf000049_0002
Figure imgf000050_0001
a κό ^r
+
Figure imgf000051_0001
X ac ac X SC K a: ffi ac ffi
Figure imgf000051_0002
VO o
( <N
Figure imgf000052_0001
Figure imgf000052_0002
K
Figure imgf000052_0003
Figure imgf000052_0004
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000055_0002
Figure imgf000055_0003
Figure imgf000056_0001
m
©
Figure imgf000056_0002
o o O o O o o o m £ CO
X X T a i X a: X m u υ u u U υ m re υ u
Figure imgf000056_0003
S CQ
9 t-~ ώ
Figure imgf000056_0004
©
11
^ υ—^ m
©
Figure imgf000057_0001
O o o O O O v. o CΛ o O
2 oo 2 m
T Z
X X X r- X X a r:*- a: o u u U υ α U U
Figure imgf000057_0002
O a: r^
Figure imgf000057_0003
00 as © CN o VO vo
Figure imgf000058_0001
Figure imgf000058_0002
Figure imgf000058_0003
a: a:
Figure imgf000058_0004
vo oo σ © CN m rt r- oo OO 00 oo
Figure imgf000059_0001
o o CΛ rr o fl- o . T O . -q-
2 2 o o o o oo 2 2 2 oo u 2 u o 2 2
£ a: r- 2
K a: X CN a CN: r* X ffi a: EC u U U U
U U U U
Figure imgf000059_0002
Figure imgf000059_0003
Figure imgf000059_0004
Figure imgf000060_0001
TABLE 2 H NMR data of compounds of Examples of Table
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
TABLE 3 Chemical names of parent compounds of Examples of Table 1 (names generated by Beilstein's Autonom)
Figure imgf000068_0001
Figure imgf000069_0002
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001

Claims

Claims:
1. A compound, or a solvate or a salt thereof, of formula (I):
Figure imgf000075_0001
(I) wherein, Ar is an optionally substituted aryl or a C5.7 cycloalkdienyl group, or an optionally substituted C5.7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group;
R is hydrogen, linear or branched \. alkyl, C3.7 cycloalkyl, C3.7 cycloalkylalkyl;
R1 represents hydrogen or up to three optional substituents selected from the list consisting of: C\. alkyl, C1. alkenyl, aryl, Cι _6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C\.β alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-Ci .5 alkylamino;
R2 represents a moiety -(CH2)n-NYι Y2 wherein n is an integer in the range of from 1 to 9, Yj and Y2 are independently selected from Cι _6-alkyl; C\. 6 alkyl substituted with hydroxy, alkoxy, C\.β alkylamino or bis (C\.β alkyl) amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; Ci .g-alkenyl; aryl or aryl-Cj_6- alkyl or Yj and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group;
R3 is branched or linear \. alkyl, C3.7 cycloalkyl, C4.7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and
R4 represents hydrogen or C\. alkyl.
R5 represents hydrogen or halogen.
2. A compound according to claim 1, wherein Ar represents optionally substituted phenyl, unsubstituted phenyl or cyclohexyl.
3. A compound according to claim 1 or claim 2, wherein Ar represents cyclohexyl.
4. A compound according to claim 1 or claim 2, wherein Ar represents phenyl.
5. A compound according to any one of claims 1 to 4, wherein R represents Ci-6 alkyl.
6. A compound according to any one of claims 1 to 5, wherein R\ represents hydrogen or Cj_6 alkoxy.
7. A compound according to any one of claims 1 to 6, wherein R\ represents hydrogen.
8. A compound according to any one of claims 1 to 6, wherein R\ represents methoxy or hydroxy.
9. A compound according to any one of claims 1 to 8, wherein R$ represents hydrogen.
10. A compound according to any one of claims 1 to 8, wherein R5 is chloro or bromo.
11. A compound according to any one of claims 1 to 10, wherein NY1 Y2 represents an optionally substituted N-linked single or fused ring heterocyclic group.
12. A compound according to any one of claims 1 to 1 1, wherein -NYj Y2 is a substituted or unsubstituted piperazinyl group.
13. A compound according to any one of claims 1 to 12, wherein -NY\ Y2 is a group of formula (a), (b) (c) or (d):
Figure imgf000076_0001
(a) (b) wherein Ti represents isopropylcarbonyl, hydroxyethyl, cyclohexyl, phenyl, benzyl, isopropyl, phenethyl, 1 -piperidinyl, hydroxyethoxyethyl, (4-hydroxy)-l- piperidinyl, 4-piperidinyl, (l-methyl)-4-piperidinyl, dimethylaminomethylcarbonyl, diethylaminoethylcarbonyl, (4-methyl)- 1 - piperazinylmethylcarbonyl, 4-moφholinylethylcarbonyl, amino, (4-methyl)- 1- piperazinyl, 1 -piperazinyl, N-methyl-N'-cyanocarboxamidine, 2-thiazolinyl, pyrrolidinyl-N-cyanomethyleneimine, pyrrolidinyl-N-methylmethyleneimine, 1 - pyrrolidinyl-2-nitrovinyl, carboxamidine, carboxyethylcarbonyl, pyrrolidinyl-N- methylsulphonylmethyleneimine, (2-carboxy)-phenylcarbonyl, aminosulphonyl, dimethylaminosulphonyl, carboxymethyl; or
Figure imgf000077_0001
(c) (d) wherein T\ together with T2 and the atoms to which each is attached form an optionally substituted single or fused ring heterocyclic group and either T3 together with T4 form an optionally substituted single or fused ring heterocyclic group;
14. A compound according to claim 13, wherein Ti represents one of the following groups:
Figure imgf000077_0002
wherein R45 represents H or a lower alkyl, m is an integer 1 to 5 and R and R8 represent a lower alkyl, or together form an heterocycle, Qi represents 2-phthalic acid, a saturated or unsaturated Cl-6 carboxylic acid or an heterocycle.
15. A compound according to claim 13 or 14, wherein Ti represents a moiety of formula (a).
16. A compound according to claim 13 or 14, wherein Ti represents a moiety of formula (b). /O
17. A compound according to claim 13 or 14, wherein Ti represents a moiety of formula (c).
18. A compound according to claim 13 or 14, wherein Ti represents a moiety of formula (d).
19. A compound according to any one of claims 1 to 18, wherein R3 is a phenyl group.
20. A compound according to any one of claims 1 to 19, wherein R4 is hydrogen.
21. A compound of formula (I) according to claim 1 , wherein:
Ar is phenyl or cyclohexyl, R is methyl, ethyl, or isopropyl, Ri is hydrogen or methoxy or hydroxy, R2 is a moiety (CH2)n wherein n is 1 , 2, 3 or 4, R3 is phenyl and R4 is hydrogen and NYi Y2 is:
(i) an optionally substituted piperazinyl group, especially a moiety of the above defined formula (a);
(ii) a moiety of the above defined formula (b); or
(iii) a moiety of the above defined formula (c); or
(iv) a moiety of the above defined formula (d).
22. A compound of formula (I) according to claim 1 , wherein:
Ar is cyclohexyl, R is methyl, ethyl or isopropyl, R\ is hydrogen, methoxy or hydroxy R2 is a moiety -(CH2)n- YιY2 wherein n is 1,R3 is phenyl and R4 is hydrogen and NYi Y2 [s:
(i) an optionally substituted piperazinyl group, especially a moiety of the above defined formula (a);
(ii) a moiety of the above defined formula (b); or
(iii) a moiety of the above defined formula (c),or
(iv) a moiety of the above defined formula (d).
23. A compound of formula (I) according to claim 1, selected from any one of Examples 1 to 95 as described herein.
24. A compound of formula (I) according to claim 1, selected from any one of examples 20, 29, 32, 33, 34, 46, 47, 48, 53, 55, 62, 67, 78, 79, 80, 81 and 95.
25. A process for the preparation of a compound of formula (I) according to claim 1, or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (II) or an active derivative thereof:
Figure imgf000079_0001
wherein R\, R'2, '3 and R'5 are Ri , R2, R3 and R5 respectively as defined in relation to formula (I) or a group convertible to Ri , R2, R3 and R5 respectively; with a compound of formula (III):
Ar' R'
R. (Ill)
wherein R', R4' and Ar' are R, R4 and Ar as defined for formula (I) or a group or atom convertible to R, R4 and Ar respectively; to form a compound of formula (lb):
Figure imgf000079_0002
wherein Ar', R', R'j, R'2, R'3, R'4 and R'5 are as defined above, and thereafter carrying out one or more of the following optional steps: (i) converting any one of Ar', R', R'\ , R'2, R'3, R4 and R'5 to Ar, R, Rl s R2, R3, R4 or R5 respectively as required, to obtain a compound of formula (I); (ii) converting a compound of formula (I) into another compound of formula (I); and (iii) preparing a salt of the compound of formula (I) and/or a solvate thereof.
26. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
27. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.
28. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the treatment or prophylaxis of the Primary and Secondary Conditions.
29. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Conditions.
30. A method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, non-toxic pharmaceutically acceptable amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
PCT/EP1999/009115 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists Ceased WO2000031037A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020017006343A KR20010075726A (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists
JP2000583865A JP2002530377A (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
NZ511777A NZ511777A (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
AU17770/00A AU768708B2 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
BR9915475-7A BR9915475A (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as antagonists of nk-3 and nk-2 receptors
HK02101024.6A HK1041257A1 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
EP99961001A EP1131295A1 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
MXPA01005095A MXPA01005095A (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists.
HU0104959A HUP0104959A3 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives their preparation, their use as nk-3 and nk-2 receptor antagonists and medicaments containing them
CA002351865A CA2351865A1 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
IL14313799A IL143137A0 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
NO20012473A NO20012473L (en) 1998-11-20 2001-05-18 Quinoline-4-carboxamide derivatives such as NK-3 and NK-2 receptor antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9825553.2 1998-11-20
GBGB9825552.4A GB9825552D0 (en) 1998-11-20 1998-11-20 Novel compounds
GB9825552.4 1998-11-20
GBGB9825553.2A GB9825553D0 (en) 1998-11-20 1998-11-20 Novel Compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09856085 A-371-Of-International 2001-09-04
US15921802A Continuation 1998-11-20 2002-05-31

Publications (1)

Publication Number Publication Date
WO2000031037A1 true WO2000031037A1 (en) 2000-06-02

Family

ID=26314705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009115 Ceased WO2000031037A1 (en) 1998-11-20 1999-11-19 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists

Country Status (18)

Country Link
EP (1) EP1131295A1 (en)
JP (1) JP2002530377A (en)
KR (1) KR20010075726A (en)
CN (1) CN1406225A (en)
AR (2) AR021355A1 (en)
AU (1) AU768708B2 (en)
BR (1) BR9915475A (en)
CA (1) CA2351865A1 (en)
CO (1) CO5150149A1 (en)
HK (1) HK1041257A1 (en)
HU (1) HUP0104959A3 (en)
IL (1) IL143137A0 (en)
MX (1) MXPA01005095A (en)
NO (1) NO20012473L (en)
NZ (1) NZ511777A (en)
PL (1) PL347721A1 (en)
TR (1) TR200101412T2 (en)
WO (1) WO2000031037A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038547A1 (en) * 2000-11-13 2002-05-16 Glaxosmithkline Spa Quinoline derivatives as nk-3 and nk-2 antagonists
WO2002038548A1 (en) * 2000-11-13 2002-05-16 Glaxosmithkline S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2002044165A1 (en) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Quinoline derivatives as nk-3 antagonists
WO2002044154A1 (en) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Novel compounds
WO2002043734A1 (en) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Novel compounds
WO2002083664A1 (en) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2002083645A1 (en) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. Novel compounds
WO2004002484A1 (en) * 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
US6777421B2 (en) 2001-04-10 2004-08-17 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2004072045A1 (en) * 2003-02-11 2004-08-26 Merck Sharp & Dohme Limited Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
WO2006050992A1 (en) * 2004-11-12 2006-05-18 Smithkline Beecham Corporation Compounds having activity at nk3 receptor and uses thereof in medicine
EP1387687A4 (en) * 2001-05-18 2006-07-05 Smithkline Beecham Corp Novel use
WO2006130080A3 (en) * 2005-06-03 2007-01-25 Astrazeneca Ab Quinoline derivatives as nk3 anatgonists
WO2007012900A1 (en) 2005-07-29 2007-02-01 Merck Sharp & Dohme Limited Quinoline derivatives as neurokinin receptor antagonists
WO2006120478A3 (en) * 2005-05-10 2007-03-29 Merck Sharp & Dohme Quinoline derivatives as neurokinin receptor antagonists
US7217740B2 (en) 2004-08-27 2007-05-15 Merck Sharp And Dohme Diarylsulfones as 5-HT2A antagonists
WO2007039123A3 (en) * 2005-09-22 2007-06-21 Smithkline Beecham Corp Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
WO2007069977A1 (en) * 2005-12-12 2007-06-21 Astrazeneca Ab Alkylsulphonamide quinolines
WO2008016006A1 (en) * 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2008097976A1 (en) * 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
EP1635834A4 (en) * 2003-06-25 2009-12-02 Smithkline Beecham Corp NEW COMPOUNDS
US7964733B2 (en) 2005-09-21 2011-06-21 Astrazeneca Ab Alkyl sulfoxide quinolines as NK-3 receptor ligands
US8703948B2 (en) 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
US8741916B2 (en) 2007-04-09 2014-06-03 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor
US8778956B2 (en) 2002-09-09 2014-07-15 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2549872B1 (en) * 2010-03-23 2015-11-25 GlaxoSmithKline LLC Trpv4 antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032948A1 (en) * 1994-05-27 1995-12-07 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives as tachykinin nk3 receptor antagonists
WO1997019926A1 (en) * 1995-11-24 1997-06-05 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists.
WO1998052942A1 (en) * 1997-05-23 1998-11-26 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032948A1 (en) * 1994-05-27 1995-12-07 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives as tachykinin nk3 receptor antagonists
WO1997019926A1 (en) * 1995-11-24 1997-06-05 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists.
WO1998052942A1 (en) * 1997-05-23 1998-11-26 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
WO2002038547A1 (en) * 2000-11-13 2002-05-16 Glaxosmithkline Spa Quinoline derivatives as nk-3 and nk-2 antagonists
WO2002038548A1 (en) * 2000-11-13 2002-05-16 Glaxosmithkline S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2002044165A1 (en) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Quinoline derivatives as nk-3 antagonists
WO2002044154A1 (en) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Novel compounds
WO2002043734A1 (en) * 2000-11-28 2002-06-06 Glaxosmithkline Spa Novel compounds
US6777421B2 (en) 2001-04-10 2004-08-17 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
US7053101B2 (en) 2001-04-10 2006-05-30 Alfonzo Jordan 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2002083663A1 (en) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2002083645A1 (en) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. Novel compounds
EP1659120A1 (en) * 2001-04-11 2006-05-24 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
WO2002083664A1 (en) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
EP1387687A4 (en) * 2001-05-18 2006-07-05 Smithkline Beecham Corp Novel use
WO2004002484A1 (en) * 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
US8778956B2 (en) 2002-09-09 2014-07-15 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2004072045A1 (en) * 2003-02-11 2004-08-26 Merck Sharp & Dohme Limited Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands
US7482457B2 (en) 2003-02-11 2009-01-27 Merck Sharp & Dohme Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands
EP1635834A4 (en) * 2003-06-25 2009-12-02 Smithkline Beecham Corp NEW COMPOUNDS
US7217740B2 (en) 2004-08-27 2007-05-15 Merck Sharp And Dohme Diarylsulfones as 5-HT2A antagonists
US7468393B2 (en) 2004-08-27 2008-12-23 Merck Sharp & Dohme Ltd. Diarylsulfones as 5-HT2A antagonists
WO2006050992A1 (en) * 2004-11-12 2006-05-18 Smithkline Beecham Corporation Compounds having activity at nk3 receptor and uses thereof in medicine
WO2006120478A3 (en) * 2005-05-10 2007-03-29 Merck Sharp & Dohme Quinoline derivatives as neurokinin receptor antagonists
WO2006130080A3 (en) * 2005-06-03 2007-01-25 Astrazeneca Ab Quinoline derivatives as nk3 anatgonists
WO2007012900A1 (en) 2005-07-29 2007-02-01 Merck Sharp & Dohme Limited Quinoline derivatives as neurokinin receptor antagonists
US7964733B2 (en) 2005-09-21 2011-06-21 Astrazeneca Ab Alkyl sulfoxide quinolines as NK-3 receptor ligands
WO2007039123A3 (en) * 2005-09-22 2007-06-21 Smithkline Beecham Corp Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
US7608628B2 (en) 2005-12-12 2009-10-27 Astrazeneca Ab Alkylsulphonamide quinolines
RU2421447C2 (en) * 2005-12-12 2011-06-20 Астразенека Аб Alkyl sulphonamide quinolines with affinity to nk-3 receptors
US8071621B2 (en) 2005-12-12 2011-12-06 Astrazeneca Ab Alkylsulphonamide quinolines
WO2007069977A1 (en) * 2005-12-12 2007-06-21 Astrazeneca Ab Alkylsulphonamide quinolines
JPWO2008016006A1 (en) * 2006-07-31 2009-12-24 小野薬品工業株式会社 Compound containing spiro-bonded cyclic group and use thereof
WO2008016006A1 (en) * 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US8703948B2 (en) 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
WO2008097976A1 (en) * 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US8741916B2 (en) 2007-04-09 2014-06-03 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Also Published As

Publication number Publication date
AR021355A1 (en) 2002-07-17
EP1131295A1 (en) 2001-09-12
NZ511777A (en) 2003-12-19
IL143137A0 (en) 2002-04-21
AU768708B2 (en) 2004-01-08
JP2002530377A (en) 2002-09-17
PL347721A1 (en) 2002-04-22
KR20010075726A (en) 2001-08-09
NO20012473D0 (en) 2001-05-18
CO5150149A1 (en) 2002-04-29
HK1041257A1 (en) 2002-07-05
MXPA01005095A (en) 2002-04-24
CA2351865A1 (en) 2000-06-02
HUP0104959A2 (en) 2002-04-29
AU1777000A (en) 2000-06-13
NO20012473L (en) 2001-07-18
HUP0104959A3 (en) 2003-01-28
AR021354A1 (en) 2002-07-17
TR200101412T2 (en) 2001-10-22
CN1406225A (en) 2003-03-26
BR9915475A (en) 2001-12-18

Similar Documents

Publication Publication Date Title
EP1131295A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
EP1019377A1 (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists.
EP1377555B1 (en) A dioxino[2,3-g]quinoline-9-carboxylic acid derivative as nk3 receptor antagonist
EP0983262B1 (en) Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
EP1385839B1 (en) 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US6613770B1 (en) Quinoline derivatives as NK-2 and NK-3 receptor ligands
EP1334088A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US20040082589A1 (en) Quinoline derivatives as nk-3 and nk-2 antagonists
EP1351953A1 (en) Quinoline derivatives as nk-3 antagonists
US20040102633A1 (en) Novel compounds
US6780875B2 (en) Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
WO2002043734A1 (en) Novel compounds
US20070197546A1 (en) Quinoline-4-carboxamide as nk-2 and nk-3 receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99815753.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 17770

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 143137

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 17770/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2001-1743

Country of ref document: CZ

Ref document number: 511777

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2351865

Country of ref document: CA

Ref document number: 2351865

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/04071

Country of ref document: ZA

Ref document number: 200104071

Country of ref document: ZA

Ref document number: IN/PCT/2001/00419/DE

Country of ref document: IN

Ref document number: 2001/01412

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020017006343

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 583865

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005095

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999961001

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017006343

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09856085

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999961001

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1743

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 17770/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017006343

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-1743

Country of ref document: CZ